A Phase 4 interventional study of APRETUDE and Cabotegravir OLI in HIV Infections, sponsored by ViiV Healthcare. Completed at 17 sites in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 15th largest by enrollment, is one of 3 that started in 2022, is one of 3 in phase 4, and was the 25th registered.
4,736 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 287 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 47th largest by enrollment of the 210 interventional ones that give a count, is one of 6 that started in 2022, is one of 18 in phase 4, and was the 227th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low and high-volume PrEP sites in the United States for men who have sex with men (MSM) and Transgender men ≥ 18 years of age. There are two types of participants in the study. Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available Cabotegravir PrEP via prescription from the PrEP provider at the corresponding site. Staff Study Participants (SSPs) will refer to site staff who are involved in administrative and clinical aspects of offering and administering PrEP to PSPs and will participate in the staff study assessments. PSPs who choose to opt for 1-month oral lead-in (OLI) will receive cabotegravir tablets for PrEP at Month 1 followed by APPRETUDE intramuscular (IM) injections on Month 2, 3 and every two months thereafter up to Month 13. PSPs who opt for Direct to injections (DTI) will receive APPRETUDE IM injections on Month 1, 2 and every two months thereafter up to Month 12. Month 6/7 refers to Month 6 (DTI)/ Month 7 (OLI). Month 12/13 refers to Month 12 (DTI)/ Month 13 (OLI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Men who have sex with men (MSM) and transgender men (TGM) who were HIV negative as PSPs received APRETUDE injection (Direct to Injection - DTI) and had the choice to receive an optional cabotegravir tablets as oral lead in (OLI). PSPs had access to enhanced toolkits and digital health implementation supports.
Drug: APRETUDE · Drug: Cabotegravir OLI
MSM and transgender men who were HIV negative as PSPs received APRETUDE injection (DTI) and had the choice to use an optional cabotegravir tablets as OLI. PSPs had access to standard toolkits for APRETUDE to use as needed.
Drug: APRETUDE · Drug: Cabotegravir OLI
Available as intramuscular injection.
Available as marketed orally administered tablets.
Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs
The FIM-Intervention (INT) was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI)
Time frame: At Month 12
Change From Baseline in FIM Score Assessed for SSPs
This outcome assesses the change in FIM-INT for SSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
Time frame: At Month 4 and Month 12 compared to baseline (Month 1)
Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12
Perception of facilitators to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked about the facilitators of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12
Perception of barriers to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs were asked about the barriers/challenges of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Mean FIM Score Assessed for PSPs
The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs
The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE
The implementation science questionnaire (ISQ) used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated if they would recommend APRETUDE to others. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on the ease or difficulty of scheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on ease or difficulty of rescheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Change From Baseline in AIM Score Assessed for PSPs
This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Change From Baseline in FIM Score Assessed for PSPs
This outcome assesses the change in FIM-INT for PSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to baseline.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Percentage of PSPs With Change From Baseline in ISQ Responses
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE and how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. Q2M = a schedule of injection administration at every 2 months.
Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)
Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12
Facilitators to feasibility and acceptability of APRETUDE measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perception of the facilitators of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12
Barriers to feasibility and acceptability of APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perspectives on the barriers and challenges of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent M13 for PSPs who received OLI).
Time frame: Up to Month 12
Mean FIM Score for Telehealth Delivery Assessed for SSPs
The FIM-TEL services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Mean AIM Score for Telehealth Delivery Assessed for SSPs
The AIM-TEL services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about which telehealth services/systems were used at their clinic/practice to deliver APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 4 and Month 12
Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the helpfulness of the telehealth services/systems used at their clinic/practice. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 4 and Month 12
Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs
The FIM telehealth services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
Time frame: At Month 4 and Month 12 compared to baseline (Month 1)
Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs
This outcome assesses the change in AIM telehealth services for SSPs over time. The AIM telehealth services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
Time frame: At Month 4 and Month 12 compared to baseline (Month 1)
Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.
Time frame: At Month 4 and Month 12 compared to Baseline (Month 1)
Mean FIM Score for Telehealth Delivery Assessed for PSPs
The FIM telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Mean AIM Score for Telehealth Delivery Assessed for PSPs
The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timepoints during which this outcome measure was evaluated were BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI)
Time frame: At Baseline (Month 1), Month 6 and Month 12
Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how comfortable it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how convenient it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Number of PSPs With Response to the ISQs Recommending Telehealth Delivery
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked if they would recommend telehealth services for APRETUDE to other people. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs
The FIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs
The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.
Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)
Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery
Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery
Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Mean AIM Score Assessed for SSPs
AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-Implementation (IMP) that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Change From Baseline in AIM Score Assessed for SSPs
AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-IMP that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.
Time frame: At Month 4 and Month 12 compared to baseline (Month 1)
Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE (Item \[I\]1= Management of scheduling injection appointments during correct injection windows, I2= Management of rescheduling appointments during correct injection windows, I3= Ability to schedule/reschedule patients who missed APRETUDE visits, I4= Ability to identify and flag missed injection visits to providers (in a timely manner), I5= Ability to manage patients presenting to APRETUDE appointments with other care needs). Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.
Time frame: At Month 4 and 12 compared to Baseline (Month 1)
Mean AIM Score Assessed for PSPs
The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE.
Time frame: At Baseline (Month 1)
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M6 (equivalent to M7 for PSPs who received OLI).
Time frame: At Month 6
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).
Time frame: At Month 12
Change From Baseline in Mean AIM Score in PSPs
This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy
In this outcome measure, usong the ISQ, PSPs were asked about the helpfulness of various knowledge materials (I1= Getting Started Brochure that gives an overview of how to get started with APRETUDE, I2 = Patient Brochure helps understand the process of receiving APRETUDE, I3 = HIV \& PrEP video gives key facts about HIV and PrEP options (DI), I4 = APRETUDE Myths and Facts video, addressing common myths about APRETUDE (DI), I5 = The What to Expect video which shows what to expect during the APRETUDE process (DI), I6 = The ViiV Connect program Video and frequently asked questions (DI), I7 = The study website to access APRETDUE information (RI), I8 = The study app to access APRETUDE information (DI). Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.
Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)
Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the usefulness of various implementation strategies used for implementing APRETUDE in their clinic/practice. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how useful various implementation strategies have been in supporting them while taking APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI
Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs provided their insights on the tools and strategies used for implementing APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs)
Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, PSPs provided their insights regarding the tools and strategies used for delivering APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of Injections Occurring Within Target Window From Target Date
This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as ± 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs Completing Target Number of Injections
Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs With Perceptions of Facilitators to Fidelity to Injections
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs provided their insights into how APRETUDE has been incorporated into their daily lives, including factors that supported its delivery. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs With Perceptions of Barriers to Fidelity to Injections
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs reported several challenges related to incorporating APRETUDE into their daily lives. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of SSPs With Perceptions of Facilitators to Fidelity to Injections
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the facilitators for adherence to APRETUDE and the support provided to enable patient adherence. These facilitators were categorized as resources, support, patient communication and patient feasibility. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of SSPs With Perceptions of Barriers to Fidelity to Injections
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the barriers and challenges in enabling patient adherence to APRETUDE. The barriers were categorized as patient barriers and staff challenges. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of SSPs Who Administer Sexual Health Assessment (SHA)
In this outcome measure, SSPs answered questions about their administration of the sexual health assessment (SHA). The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of Eligible PSPs for Which SHA Are Administered
In this outcome measure, data shown below describes the number of PSPs to which the SHA was administered. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA
In this outcome measure, data shown below describes the number of MSM and TGM who reported having had sex in the last 6 months. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months
In this outcome measure, data presented below shows the number of PSPs who expressed interest in PreP by responding to the question "Have you taken oral PreP in the last 6 months" and number of PSPs who had not heard of PreP.
Time frame: Up to Month 12
Number of PSPs Who Initiate APRETUDE After Taking the SHA
In this outcome measure, PSPs were asked if they had taken oral PreP in the last 6 months. PSPs who answered 'No' or 'I prefer not to answer' were further asked if they had ever taken oral PreP. Timeframe for evaluation of this outcome measure is through M12(equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs With Perceptions of SHA
Perceptions of the sexual health assessment (SHA) among PSPs were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of SSPs With Perceptions of SHA
In this outcome measure, SSPs provided insights regarding the use and implementation of SHA tool in their clinic/practice. The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of Modifications Reported by SSPs Using FRAME-IS
The Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize all modifications reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is from M2 to M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Number of Modifications for Each Category Reported by SSPs Using FRAME-IS
The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the types of modifications and adaptations reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS
The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the perceptions and motivations of adaptations to implementation reported by SSPs using FRAME-IS. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies
PSP perceptions of adaptations to implementation strategies were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discussed their use of study resources and recommendations to staff for delivery of APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE
In this outcome measure, PSPs who completed the SHA and ISQ, describe the history of PrEP use and of sexual health assessment use for determination of PreP use during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs)
Reasons for choosing and switching to APRETUDE were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews among PSPs. In this outcome measure, PSPs shared previous oral PrEP experiences, comparisons of other forms of PrEP to APRETUDE, and reasons for preferring APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs answered ISQ regarding reasons for choosing to take APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs Assessed for Perception of Facilitators
General perceptions of facilitators for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss views of long-term use of APRETUDE, reasons to choose APRETUDE, and experiences with clinic staff. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of PSPs Assessed for Perception of Barriers
General perceptions of barriers for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss challenging views of or experiences with APRETUDE receipt. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Number of SSPs Assessed for Perception of Facilitators
General perceptions of facilitators for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss clinic culture and implementation motivations. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Number of SSPs Assessed for Perception of Barriers
General perceptions of barriers for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss feelings and perspectives while implementing APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
A total of 17 Clinics were randomized to Dynamic Implementation and Routine Implementation arms. In these clinics, a total of 201 patient study participants (PSPs) were enrolled in the study and all of them received study treatment and 86 Staff Study Participants (SSPs) were enrolled that included healthcare providers, nurses, staff performing injections, clinic administrators, pharmacists and laboratory staff.
| Milestone | Dynamic Implementation (DI) | Routine Implementation (RI) |
|---|---|---|
| Started | 173 | 114 |
| Psp | 117 | 84 |
| Ssp | 56 | 30 |
| Completed | 137 | 95 |
| Not completed | 36 | 19 |
| Withdrew: Adverse event | 5 | 6 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Withdrawal by subject | 26 | 8 |
The FIM-Intervention (INT) was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI)
| Scores on a scale | DI - SSP | RI - SSP |
|---|---|---|
| Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs | 4.37 ± 0.68 | 4.27 ± 0.68 |
This outcome assesses the change in FIM-INT for SSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
| Scores on a scale | DI - SSP | RI - SSP |
|---|---|---|
| Month 4 compared to baseline (BL) | -0.29 ± 0.92 | 0.08 ± 0.59 |
| Month 12 compared to BL | -0.01 ± 0.69 | -0.11 ± 0.86 |
Perception of facilitators to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked about the facilitators of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Clinic being flexible with scheduling (injection/ lab visits) | 5 | 1 |
| Scheduling appointments in advance | 6 | 0 |
| Training and consistent information provided to staff | 5 | 0 |
| Increased communication for vulnerable populations | 3 | 1 |
| Previous experience with CABENUVA/ APRETUDE | 2 | 2 |
Perception of barriers to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs were asked about the barriers/challenges of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Staff burden to integrate the new process | 7 | 3 |
| Complex team coordination | 4 | 2 |
| Insurance challenges related to infrastructure | 4 | 2 |
| Infrastructure Logistic challenges | 3 | 2 |
| Follow-up with pharmacies needed to obtain APRETUDE | 2 | 2 |
The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Baseline | 4.33 ± 0.77 | 4.51 ± 0.70 |
| Month 6 | 4.35 ± 0.75 | 4.46 ± 0.73 |
| Month 12 | 4.36 ± 0.79 | 4.46 ± 0.72 |
The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Baseline | 4.46 ± 0.69 | 4.41 ± 0.68 |
| Month 6 | 4.57 ± 0.64 | 4.57 ± 0.55 |
| Month 12 | 4.61 ± 0.63 | 4.60 ± 0.67 |
The implementation science questionnaire (ISQ) used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| At Baseline - Overall, how are you feeling about taking APRETUDE? — Very Positive | 79 | 64 |
| At Baseline - Overall, how are you feeling about taking APRETUDE? — Somewhat Positive | 19 | 10 |
| At Baseline - Overall, how are you feeling about taking APRETUDE? — Neither positive nor negative | 7 | 1 |
| At Baseline - Overall, how are you feeling about taking APRETUDE? — Somewhat negative | 0 | 0 |
| At Baseline - Overall, how are you feeling about taking APRETUDE? — Very negative | 0 | 0 |
| At Baseline - Overall, how are you feeling about taking APRETUDE? — Missing | 12 | 9 |
| At Month 6 - Overall, how are you feeling about taking APRETUDE? — Very Positive | 72 | 52 |
| At Month 6 - Overall, how are you feeling about taking APRETUDE? — Somewhat Positive | 16 | 9 |
| At Month 6 - Overall, how are you feeling about taking APRETUDE? — Neither positive nor negative | 2 | 1 |
| At Month 6 - Overall, how are you feeling about taking APRETUDE? — Somewhat negative | 2 | 1 |
| At Month 6 - Overall, how are you feeling about taking APRETUDE? — Very negative | 0 | 0 |
| At Month 6 - Overall, how are you feeling about taking APRETUDE? — Missing | 25 | 21 |
| At Month 12 - Overall, how are you feeling about taking APRETUDE? — Very Positive | 66 | 55 |
| At Month 12 - Overall, how are you feeling about taking APRETUDE? — Somewhat Positive | 10 | 7 |
| At Month 12 - Overall, how are you feeling about taking APRETUDE? — Neither positive nor negative | 0 | 1 |
| At Month 12 - Overall, how are you feeling about taking APRETUDE? — Somewhat negative | 1 | 0 |
| At Month 12 - Overall, how are you feeling about taking APRETUDE? — Very negative | 0 | 0 |
| At Month 12 - Overall, how are you feeling about taking APRETUDE? — Missing | 40 | 21 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Very acceptable | 60 | 55 |
| At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Acceptable | 31 | 19 |
| At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Somewhat acceptable | 10 | 2 |
| At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — A little acceptable | 4 | 0 |
| At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Not at all acceptable | 0 | 0 |
| At Baseline - How acceptable is coming to the clinic every 2 months for an injection? — Missing | 12 | 8 |
| At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Very acceptable | 49 | 40 |
| At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Acceptable | 31 | 16 |
| At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Somewhat acceptable | 8 | 6 |
| At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — A little acceptable | 3 | 0 |
| At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Not at all acceptable | 1 | 1 |
| At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? — Missing | 0 | 0 |
| At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Very acceptable | 41 | 39 |
| At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Acceptable | 21 | 18 |
| At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Somewhat acceptable | 11 | 5 |
| At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — A little acceptable | 3 | 1 |
| At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Not at all acceptable | 0 | 0 |
| At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? — Missing | 0 | 0 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated if they would recommend APRETUDE to others. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Completely agree | 72 | 49 |
| At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Agree | 18 | 12 |
| At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Neither agree nor disagree | 2 | 0 |
| At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Disagree | 0 | 1 |
| At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Completely disagree | 0 | 1 |
| At Month 6 - I would recommend APRETUDE to other people who could benefit from it — Missing | 25 | 21 |
| At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Completely agree | 64 | 52 |
| At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Agree | 12 | 9 |
| At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Neither agree nor disagree | 1 | 2 |
| At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Disagree | 0 | 0 |
| At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Completely disagree | 0 | 0 |
| At Month 12 - I would recommend APRETUDE to other people who could benefit from it — Missing | 40 | 21 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on the ease or difficulty of scheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6- How easy or difficult is it to schedule appointments for your injections? — Very easy | 60 | 46 |
| Month 6- How easy or difficult is it to schedule appointments for your injections? — Somewhat easy | 20 | 13 |
| Month 6- How easy or difficult is it to schedule appointments for your injections? — Neither easy nor difficult | 5 | 3 |
| Month 6- How easy or difficult is it to schedule appointments for your injections? — Somewhat difficult | 6 | 1 |
| Month 6- How easy or difficult is it to schedule appointments for your injections? — Very difficult | 2 | 0 |
| Month 6- How easy or difficult is it to schedule appointments for your injections? — I have not scheduled any appointments at the clinic/practice | 0 | 0 |
| Month 6- How easy or difficult is it to schedule appointments for your injections? — Missing | 24 | 21 |
| Month 12- How easy or difficult is it to schedule appointments for your injections? — Very easy | 49 | 46 |
| Month 12- How easy or difficult is it to schedule appointments for your injections? — Somewhat easy | 15 | 10 |
| Month 12- How easy or difficult is it to schedule appointments for your injections? — Neither easy nor difficult | 6 | 4 |
| Month 12- How easy or difficult is it to schedule appointments for your injections? — Somewhat difficult | 5 | 2 |
| Month 12- How easy or difficult is it to schedule appointments for your injections? — Very difficult | 1 | 1 |
| Month 12- How easy or difficult is it to schedule appointments for your injections? — I have not scheduled any appointments at the clinic/practice | 1 | 0 |
| Month 12- How easy or difficult is it to schedule appointments for your injections? — Missing | 40 | 21 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on ease or difficulty of rescheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Very easy | 44 | 25 |
| Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Somewhat easy | 14 | 17 |
| Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Neither easy nor difficult | 1 | 4 |
| Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Somewhat difficult | 6 | 2 |
| Month 6 - How easy or difficult is it to reschedule appointments for your injections? — Very difficult | 3 | 1 |
| Month 6 - How easy or difficult is it to reschedule appointments for your injections? — I have not needed to reschedule any appointments | 25 | 14 |
| Month 12- How easy or difficult is it to reschedule appointments for your injections? — Very easy | 39 | 30 |
| Month 12- How easy or difficult is it to reschedule appointments for your injections? — Somewhat easy | 13 | 17 |
| Month 12- How easy or difficult is it to reschedule appointments for your injections? — Neither easy nor difficult | 4 | 4 |
| Month 12- How easy or difficult is it to reschedule appointments for your injections? — Somewhat difficult | 8 | 6 |
| Month 12- How easy or difficult is it to reschedule appointments for your injections? — Very difficult | 2 | 1 |
| Month 12- How easy or difficult is it to reschedule appointments for your injections? — I have not needed to reschedule any appointments | 10 | 5 |
This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6 compared to BL | 0.17 ± 0.66 | 0.20 ± 0.72 |
| Month 12 compared to BL | 0.27 ± 0.63 | 0.19 ± 0.87 |
This outcome assesses the change in FIM-INT for PSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to baseline.
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6 compared to BL | 0.01 ± 0.80 | 0.00 ± 0.89 |
| Month 12 compared to BL | 0.01 ± 0.71 | -0.01 ± 0.92 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE and how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. Q2M = a schedule of injection administration at every 2 months.
| Percentage of participants | DI- PSP | RI- PSP |
|---|---|---|
| Change BL to M6 - How the participant felt about taking APRETUDE - Very positive | 3.0 | -2.8 |
| Change BL to M6 - How the participant felt about taking APRETUDE - Somewhat positive | -0.7 | 1.0 |
| Change BL to M6-How the participant felt about taking APRETUDE- Neither positive nor negative | -4.5 | 0.3 |
| Change BL to M6 - How the participant felt about taking APRETUDE - Somewhat negative | 2.2 | 1.6 |
| Change BL to M6 - How the participant felt about taking APRETUDE - Very negative | 0.0 | 0.0 |
| Change BL to M12 - How the participant felt about taking APRETUDE-Very positive | 10.5 | 2.0 |
| Change BL to M12 - How the participant felt about taking APRETUDE-Somewhat positive | -5.1 | -2.2 |
| Change BL to M12-How the participant felt about taking APRETUDE-Neither positive nor negative | -6.7 | 0.3 |
| Change BL to M12 - How the participant felt about taking APRETUDE-Somewhat negative | 1.3 | 0.0 |
| Change BL to M12 - How the participant felt about taking APRETUDE-Very negative | 0.0 | 0.0 |
| Change BL to M6 - Participant' acceptability for injection visits Q2M - Very acceptable | -3.9 | -8.9 |
| Change BL to M6 - Participant' acceptability for injection visits Q2M - Acceptable | 4.2 | 0.4 |
| Change BL to M6 - Participant' acceptability for injection visits Q2M - Somewhat acceptable | -0.8 | 6.9 |
| Change BL to M6 - Participant' acceptability for injection visits Q2M - A little acceptable | -0.5 | 0.0 |
| Change BL to M6 - Participant' acceptability for injection visits Q2M - Not at all acceptable | 1.1 | 1.6 |
| Change BL to M12 - Participant' acceptability for injection visits Q2M - Very acceptable | -3.2 | -10.5 |
| Change BL to M12 - Participant' acceptability for injection visits Q2M - Acceptable | -1.9 | 3.6 |
| Change BL to M12 - Participant' acceptability for injection visits Q2M - Somewhat acceptable | 4.9 | 5.3 |
| Change BL to M12 - Participant' acceptability for injection visits Q2M - A little acceptable | 0.1 | 1.6 |
| Change BL to M12 - Participant' acceptability for injection visits Q2M - Not at all acceptable | 0.0 | 0.0 |
Facilitators to feasibility and acceptability of APRETUDE measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perception of the facilitators of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| APRETUDE positive experience so far | 23 | 20 |
| Positive Experiences and General Satisfaction | 14 | 12 |
| Convenience and Ease of Use | 15 | 11 |
| Perceived effectiveness provides peace of mind | 7 | 2 |
| Discomfort becoming more manageable | 1 | 5 |
| APRETUDE met their expectations | 15 | 18 |
| Reduced anxiety about taking oral PrEP | 5 | 15 |
| HIV protection | 10 | 7 |
| APRETUDE more convenient than expected | 2 | 4 |
Barriers to feasibility and acceptability of APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perspectives on the barriers and challenges of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12 | 1 | 3 |
The FIM-TEL services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Scores on a scale | DI - SSP | RI - SSP |
|---|---|---|
| Baseline | 4.01 ± 0.83 | 3.43 ± 1.23 |
| Month 4 | 4.13 ± 0.90 | 4.08 ± 1.20 |
| Month 12 | 4.26 ± 0.70 | 4.22 ± 1.30 |
The AIM-TEL services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Scores on a scale | DI - SSP | RI - SSP |
|---|---|---|
| Baseline | 4.09 ± 0.82 | 3.26 ± 1.38 |
| Month 4 | 4.16 ± 0.78 | 3.98 ± 1.16 |
| Month 12 | 4.07 ± 0.78 | 4.17 ± 1.28 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — Yes | 54 | 28 |
| Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — No | 1 | 0 |
| Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — I Don't Know | 1 | 2 |
| Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — Yes | 29 | 10 |
| Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — No | 15 | 14 |
| Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — I Don't Know | 7 | 5 |
| Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — Yes | 30 | 9 |
| Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — No | 11 | 12 |
| Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? — I Don't Know | 11 | 8 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about which telehealth services/systems were used at their clinic/practice to deliver APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Yes, at my clinic's service/system | 14 | 0 |
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Yes, services/systems offered through PILLAR study | 1 | 0 |
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — No | 8 | 0 |
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — I don't know | 6 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — Yes, at my clinic's service/system | 23 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — Yes, services/systems offered through PILLAR study | 1 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — No | 1 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — I don't know | 4 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — Yes, at my clinic's service/system | 4 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — Yes, services/systems offered through PILLAR study | 3 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — No | 17 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — I don't know | 5 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — Yes, at my clinic's service/system | 21 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — Yes, services/systems offered through PILLAR study | 1 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — No | 1 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — I don't know | 6 | 0 |
| Month 4 - HIV testing services: at home nurse testing — Yes, at my clinic's service/system | 8 | 0 |
| Month 4 - HIV testing services: at home nurse testing — Yes, services/systems offered through PILLAR study | 3 | 0 |
| Month 4 - HIV testing services: at home nurse testing — No | 14 | 0 |
| Month 4 - HIV testing services: at home nurse testing — I don't know | 4 | 0 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Yes, at my clinic's service/system | 21 | 5 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Yes, services/systems offered through PILLAR study | 1 | 1 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — No | 5 | 3 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — I don't know | 3 | 0 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — Yes, at my clinic's service/system | 24 | 6 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — Yes, services/systems offered through PILLAR study | 2 | 1 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — No | 2 | 2 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — I don't know | 2 | 0 |
| Month 12 - Injection Administration: home health nurse to administer injection — Yes, at my clinic's service/system | 6 | 1 |
| Month 12 - Injection Administration: home health nurse to administer injection — Yes, services/systems offered through PILLAR study | 6 | 1 |
| Month 12 - Injection Administration: home health nurse to administer injection — No | 16 | 7 |
| Month 12 - Injection Administration: home health nurse to administer injection — I don't know | 2 | 0 |
| Month 12 - Injection appointment reminders: text/digital/email — Yes, at my clinic's service/system | 23 | 5 |
| Month 12 - Injection appointment reminders: text/digital/email — Yes, services/systems offered through PILLAR study | 1 | 1 |
| Month 12 - Injection appointment reminders: text/digital/email — No | 2 | 3 |
| Month 12 - Injection appointment reminders: text/digital/email — I don't know | 4 | 0 |
| Month 12 - HIV testing services: at home nurse testing — Yes, at my clinic's service/system | 9 | 1 |
| Month 12 - HIV testing services: at home nurse testing — Yes, services/systems offered through PILLAR study | 6 | 1 |
| Month 12 - HIV testing services: at home nurse testing — No | 13 | 7 |
| Month 12 - HIV testing services: at home nurse testing — I don't know | 2 | 0 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the helpfulness of the telehealth services/systems used at their clinic/practice. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Very helpful | 10 | 0 |
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Helpful | 3 | 0 |
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Somewhat helpful | 1 | 0 |
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — A little helpful | 0 | 0 |
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — Not at all helpful | 0 | 0 |
| Month 4 - Online system for scheduling/rescheduling consultations and injection appointments — I have not personally used this | 1 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — Very helpful | 14 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — Helpful | 5 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — Somewhat helpful | 2 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — A little helpful | 0 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — Not at all helpful | 0 | 0 |
| Month 4 - Video/virtual consultations for initial and follow-up visits — I have not personally used this | 3 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — Very helpful | 2 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — Helpful | 2 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — Somewhat helpful | 1 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — A little helpful | 0 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — Not at all helpful | 0 | 0 |
| Month 4 - Injection Administration: home health nurse to administer injection — I have not personally used this | 2 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — Very helpful | 14 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — Helpful | 3 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — Somewhat helpful | 1 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — A little helpful | 0 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — Not at all helpful | 1 | 0 |
| Month 4 - Injection appointment reminders: text/digital/email — I have not personally used this | 3 | 0 |
| Month 4 - HIV testing services: at home nurse testing — Very helpful | 3 | 0 |
| Month 4 - HIV testing services: at home nurse testing — Helpful | 2 | 0 |
| Month 4 - HIV testing services: at home nurse testing — Somewhat helpful | 1 | 0 |
| Month 4 - HIV testing services: at home nurse testing — A little helpful | 0 | 0 |
| Month 4 - HIV testing services: at home nurse testing — Not at all helpful | 1 | 0 |
| Month 4 - HIV testing services: at home nurse testing — I have not personally used this | 4 | 0 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Very helpful | 9 | 4 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Helpful | 7 | 2 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Somewhat helpful | 4 | 0 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — A little helpful | 0 | 0 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — Not at all helpful | 0 | 0 |
| Month 12 - Online system for scheduling/rescheduling consultations and injection appointments — I have not personally used this | 2 | 0 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — Very helpful | 13 | 4 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — Helpful | 6 | 1 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — Somewhat helpful | 3 | 2 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — A little helpful | 0 | 0 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — Not at all helpful | 0 | 0 |
| Month 12 - Video/virtual consultations for initial and follow-up visits — I have not personally used this | 4 | 0 |
| Month 12 - Injection Administration: home health nurse to administer injection — Very helpful | 5 | 1 |
| Month 12 - Injection Administration: home health nurse to administer injection — Helpful | 2 | 0 |
| Month 12 - Injection Administration: home health nurse to administer injection — Somewhat helpful | 1 | 0 |
| Month 12 - Injection Administration: home health nurse to administer injection — A little helpful | 0 | 0 |
| Month 12 - Injection Administration: home health nurse to administer injection — Not at all helpful | 0 | 0 |
| Month 12 - Injection Administration: home health nurse to administer injection — I have not personally used this | 4 | 1 |
| Month 12 - Injection appointment reminders: text/digital/email — Very helpful | 16 | 4 |
| Month 12 - Injection appointment reminders: text/digital/email — Helpful | 4 | 2 |
| Month 12 - Injection appointment reminders: text/digital/email — Somewhat helpful | 1 | 0 |
| Month 12 - Injection appointment reminders: text/digital/email — A little helpful | 1 | 0 |
| Month 12 - Injection appointment reminders: text/digital/email — Not at all helpful | 0 | 0 |
| Month 12 - Injection appointment reminders: text/digital/email — I have not personally used this | 2 | 0 |
| Month 12 - HIV testing services: at home nurse testing — Very helpful | 9 | 1 |
| Month 12 - HIV testing services: at home nurse testing — Helpful | 1 | 0 |
| Month 12 - HIV testing services: at home nurse testing — Somewhat helpful | 1 | 0 |
| Month 12 - HIV testing services: at home nurse testing — A little helpful | 0 | 0 |
| Month 12 - HIV testing services: at home nurse testing — Not at all helpful | 0 | 0 |
| Month 12 - HIV testing services: at home nurse testing — I have not personally used this | 4 | 1 |
The FIM telehealth services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
| Scores on a scale | DI - SSP | RI - SSP |
|---|---|---|
| Month 4 compared to BL | -0.11 ± 1.21 | 0.20 ± 1.21 |
| Month 12 compared to BL | -0.06 ± 1.03 | 0.16 ± 0.64 |
This outcome assesses the change in AIM telehealth services for SSPs over time. The AIM telehealth services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
| Scores on a scale | DI - SSP | RI - SSP |
|---|---|---|
| Month 4 compared to BL | -0.13 ± 0.92 | 0.53 ± 1.21 |
| Month 12 compared to BL | -0.38 ± 0.97 | 0.41 ± 1.02 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.
| Percentage of participants | DI- SSP | RI- SSP |
|---|---|---|
| Change BL to M4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - YES | -39.6 | -58.9 |
| Change BL to M4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - NO | 27.6 | 48.3 |
| Change BL to M4-Does clinic/practice use any form of telehealth for APRETUDE delivery?-I DON'T KNOW | 11.9 | 10.6 |
| Change BL to M12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - YES | -38.7 | -62.3 |
| Change BL to M12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - NO | 19.4 | 41.4 |
| Change BL to M12-Does clinic/practice use any form of telehealth for APRETUDE delivery?-I DON'T KNOW | 19.4 | 20.9 |
The FIM telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Baseline | 4.40 ± 0.72 | 4.15 ± 0.97 |
| Month 6 | 4.56 ± 0.56 | 4.19 ± 0.76 |
| Month 12 | 4.25 ± 0.89 | 4.38 ± 0.70 |
The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timepoints during which this outcome measure was evaluated were BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI)
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Baseline | 4.32 ± 0.76 | 4.13 ± 0.91 |
| Month 6 | 4.56 ± 0.57 | 4.25 ± 0.70 |
| Month 12 | 4.21 ± 0.93 | 4.27 ± 0.67 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Baseline- Have you used any of the telehealth care options that your clinic offers? — Yes | 72 | 48 |
| Baseline- Have you used any of the telehealth care options that your clinic offers? — No | 14 | 10 |
| Baseline- Have you used any of the telehealth care options that your clinic offers? — I don't know | 0 | 0 |
| Baseline- Have you used any of the telehealth care options that your clinic offers? — Missing | 0 | 0 |
| Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? — Yes | 41 | 24 |
| Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? — No | 49 | 34 |
| Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? — I don't know | 4 | 7 |
| Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? — Missing | 23 | 19 |
| Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test — Yes | 17 | 9 |
| Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test — No | 22 | 14 |
| Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test — I don't know | 1 | 1 |
| Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test — Missing | 1 | 0 |
| Month 6- TEL services received: Nurse coming home to give an HIV test — Yes | 3 | 2 |
| Month 6- TEL services received: Nurse coming home to give an HIV test — No | 36 | 21 |
| Month 6- TEL services received: Nurse coming home to give an HIV test — I don't know | 1 | 1 |
| Month 6- TEL services received: Nurse coming home to give an HIV test — Missing | 1 | 0 |
| Month 6- TEL services received: Receiving reminders about scheduled injection appointment — Yes | 36 | 22 |
| Month 6- TEL services received: Receiving reminders about scheduled injection appointment — No | 4 | 1 |
| Month 6- TEL services received: Receiving reminders about scheduled injection appointment — I don't know | 0 | 1 |
| Month 6- TEL services received: Receiving reminders about scheduled injection appointment — Missing | 1 | 0 |
| Month 6- TEL services received: Scheduling injection appointment online — Yes | 24 | 15 |
| Month 6- TEL services received: Scheduling injection appointment online — No | 15 | 8 |
| Month 6- TEL services received: Scheduling injection appointment online — I don't know | 1 | 1 |
| Month 6- TEL services received: Scheduling injection appointment online — Missing | 1 | 0 |
| Month 6- TEL services received: Nurse coming home to give the injection — Yes | 2 | 2 |
| Month 6- TEL services received: Nurse coming home to give the injection — No | 38 | 21 |
| Month 6- TEL services received: Nurse coming home to give the injection — I don't know | 0 | 1 |
| Month 6- TEL services received: Nurse coming home to give the injection — Missing | 1 | 0 |
| Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? — Yes | 29 | 25 |
| Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? — No | 47 | 38 |
| Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? — I don't know | 1 | 0 |
| Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? — Missing | 40 | 21 |
| Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test — Yes | 11 | 10 |
| Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test — No | 17 | 13 |
| Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test — I don't know | 1 | 2 |
| Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test — Missing | 0 | 0 |
| Month 12- TEL services received: Nurse coming home to give an HIV test — Yes | 3 | 2 |
| Month 12- TEL services received: Nurse coming home to give an HIV test — No | 26 | 23 |
| Month 12- TEL services received: Nurse coming home to give an HIV test — I don't know | 0 | 0 |
| Month 12- TEL services received: Nurse coming home to give an HIV test — Missing | 0 | 0 |
| Month 12- TEL services received: Receiving reminders about scheduled injection appointment — Yes | 28 | 25 |
| Month 12- TEL services received: Receiving reminders about scheduled injection appointment — No | 1 | 0 |
| Month 12- TEL services received: Receiving reminders about scheduled injection appointment — I don't know | 0 | 0 |
| Month 12- TEL services received: Receiving reminders about scheduled injection appointment — Missing | 0 | 0 |
| Month 12- TEL services received: Scheduling injection appointment online — Yes | 16 | 13 |
| Month 12- TEL services received: Scheduling injection appointment online — No | 13 | 12 |
| Month 12- TEL services received: Scheduling injection appointment online — I don't know | 0 | 0 |
| Month 12- TEL services received: Scheduling injection appointment online — Missing | 0 | 0 |
| Month 12- TEL services received: Nurse coming home to give the injection — Yes | 3 | 2 |
| Month 12- TEL services received: Nurse coming home to give the injection — No | 25 | 23 |
| Month 12- TEL services received: Nurse coming home to give the injection — I don't know | 1 | 0 |
| Month 12- TEL services received: Nurse coming home to give the injection — Missing | 0 | 0 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how comfortable it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Very comfortable | 12 | 8 |
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Somewhat comfortable | 4 | 1 |
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Neither comfortable nor uncomfortable | 1 | 0 |
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Somewhat uncomfortable | 0 | 0 |
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Not comfortable at all | 0 | 0 |
| Month 6- A nurse coming home to give an HIV test — Very comfortable | 2 | 1 |
| Month 6- A nurse coming home to give an HIV test — Somewhat comfortable | 0 | 1 |
| Month 6- A nurse coming home to give an HIV test — Neither comfortable nor uncomfortable | 1 | 0 |
| Month 6- A nurse coming home to give an HIV test — Somewhat uncomfortable | 0 | 0 |
| Month 6- A nurse coming home to give an HIV test — Not comfortable at all | 0 | 0 |
| Month 6- Receiving reminders about scheduled injection appointment — Very comfortable | 33 | 20 |
| Month 6- Receiving reminders about scheduled injection appointment — Somewhat comfortable | 3 | 2 |
| Month 6- Receiving reminders about scheduled injection appointment — Neither comfortable nor uncomfortable | 0 | 0 |
| Month 6- Receiving reminders about scheduled injection appointment — Somewhat uncomfortable | 0 | 0 |
| Month 6- Receiving reminders about scheduled injection appointment — Not comfortable at all | 0 | 0 |
| Month 6- Scheduling injection appointment online — Very comfortable | 20 | 13 |
| Month 6- Scheduling injection appointment online — Somewhat comfortable | 3 | 1 |
| Month 6- Scheduling injection appointment online — Neither comfortable nor uncomfortable | 0 | 1 |
| Month 6- Scheduling injection appointment online — Somewhat uncomfortable | 1 | 0 |
| Month 6- Scheduling injection appointment online — Not comfortable at all | 0 | 0 |
| Month 6- A nurse coming home to give the injection — Very comfortable | 2 | 1 |
| Month 6- A nurse coming home to give the injection — Somewhat comfortable | 0 | 0 |
| Month 6- A nurse coming home to give the injection — Neither comfortable nor uncomfortable | 0 | 0 |
| Month 6- A nurse coming home to give the injection — Somewhat uncomfortable | 0 | 1 |
| Month 6- A nurse coming home to give the injection — Not comfortable at all | 0 | 0 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Very comfortable | 11 | 8 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Somewhat comfortable | 0 | 0 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Neither comfortable nor uncomfortable | 0 | 2 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Somewhat uncomfortable | 0 | 0 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Not comfortable at all | 0 | 0 |
| Month 12- A nurse coming to home to give an HIV test — Very comfortable | 2 | 2 |
| Month 12- A nurse coming to home to give an HIV test — Somewhat comfortable | 1 | 0 |
| Month 12- A nurse coming to home to give an HIV test — Neither comfortable nor uncomfortable | 0 | 0 |
| Month 12- A nurse coming to home to give an HIV test — Somewhat uncomfortable | 0 | 0 |
| Month 12- A nurse coming to home to give an HIV test — Not comfortable at all | 0 | 0 |
| Month 12- Receiving reminders about scheduled injection appointment — Very comfortable | 26 | 21 |
| Month 12- Receiving reminders about scheduled injection appointment — Somewhat comfortable | 2 | 2 |
| Month 12- Receiving reminders about scheduled injection appointment — Neither comfortable nor uncomfortable | 0 | 1 |
| Month 12- Receiving reminders about scheduled injection appointment — Somewhat uncomfortable | 0 | 1 |
| Month 12- Receiving reminders about scheduled injection appointment — Not comfortable at all | 0 | 0 |
| Month 12- Scheduling injection appointment online — Very comfortable | 15 | 11 |
| Month 12- Scheduling injection appointment online — Somewhat comfortable | 1 | 1 |
| Month 12- Scheduling injection appointment online — Neither comfortable nor uncomfortable | 0 | 1 |
| Month 12- Scheduling injection appointment online — Somewhat uncomfortable | 0 | 0 |
| Month 12- Scheduling injection appointment online — Not comfortable at all | 0 | 0 |
| Month 12- A nurse coming home to give the injection — Very comfortable | 3 | 2 |
| Month 12- A nurse coming home to give the injection — Somewhat comfortable | 0 | 0 |
| Month 12- A nurse coming home to give the injection — Neither comfortable nor uncomfortable | 0 | 0 |
| Month 12- A nurse coming home to give the injection — Somewhat uncomfortable | 0 | 0 |
| Month 12- A nurse coming home to give the injection — Not comfortable at all | 0 | 0 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how convenient it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Very convenient | 12 | 8 |
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Somewhat convenient | 3 | 0 |
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Neither convenient nor inconvenient | 2 | 1 |
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Somewhat inconvenient | 0 | 0 |
| Month 6- Doctor ordering HIV test at a lab near home to take the test — Very inconvenient | 0 | 0 |
| Month 6- A nurse coming home to give an HIV test — Very convenient | 1 | 2 |
| Month 6- A nurse coming home to give an HIV test — Somewhat convenient | 1 | 0 |
| Month 6- A nurse coming home to give an HIV test — Neither convenient nor inconvenient | 1 | 0 |
| Month 6- A nurse coming home to give an HIV test — Somewhat inconvenient | 0 | 0 |
| Month 6- A nurse coming home to give an HIV test — Very inconvenient | 0 | 0 |
| Month 6- Receiving reminders about scheduled injection appointment — Very convenient | 31 | 18 |
| Month 6- Receiving reminders about scheduled injection appointment — Somewhat convenient | 4 | 4 |
| Month 6- Receiving reminders about scheduled injection appointment — Neither convenient nor inconvenient | 1 | 0 |
| Month 6- Receiving reminders about scheduled injection appointment — Somewhat inconvenient | 0 | 0 |
| Month 6- Receiving reminders about scheduled injection appointment — Very inconvenient | 0 | 0 |
| Month 6- Scheduling your injection appointment online — Very convenient | 19 | 13 |
| Month 6- Scheduling your injection appointment online — Somewhat convenient | 3 | 1 |
| Month 6- Scheduling your injection appointment online — Neither convenient nor inconvenient | 2 | 0 |
| Month 6- Scheduling your injection appointment online — Somewhat inconvenient | 0 | 1 |
| Month 6- Scheduling your injection appointment online — Very inconvenient | 0 | 0 |
| Month 6- A nurse coming home to give the injection — Very convenient | 2 | 1 |
| Month 6- A nurse coming home to give the injection — Somewhat convenient | 0 | 0 |
| Month 6- A nurse coming home to give the injection — Neither convenient nor inconvenient | 0 | 0 |
| Month 6- A nurse coming home to give the injection — Somewhat inconvenient | 0 | 0 |
| Month 6- A nurse coming home to give the injection — Very inconvenient | 0 | 1 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Very convenient | 11 | 9 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Somewhat convenient | 0 | 0 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Neither convenient nor inconvenient | 0 | 1 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Somewhat inconvenient | 0 | 0 |
| Month 12- Doctor ordering HIV test at a lab near home to take the test — Very inconvenient | 0 | 0 |
| Month 12- A nurse coming home to give an HIV test — Very convenient | 2 | 2 |
| Month 12- A nurse coming home to give an HIV test — Somewhat convenient | 1 | 0 |
| Month 12- A nurse coming home to give an HIV test — Neither convenient nor inconvenient | 0 | 0 |
| Month 12- A nurse coming home to give an HIV test — Somewhat inconvenient | 0 | 0 |
| Month 12- A nurse coming home to give an HIV test — Very inconvenient | 0 | 0 |
| Month 12- Receiving reminders about scheduled injection appointment — Very convenient | 28 | 22 |
| Month 12- Receiving reminders about scheduled injection appointment — Somewhat convenient | 0 | 2 |
| Month 12- Receiving reminders about scheduled injection appointment — Neither convenient nor inconvenient | 0 | 1 |
| Month 12- Receiving reminders about scheduled injection appointment — Somewhat inconvenient | 0 | 0 |
| Month 12- Receiving reminders about scheduled injection appointment — Very inconvenient | 0 | 0 |
| Month 12- Scheduling your injection appointment online — Very convenient | 14 | 11 |
| Month 12- Scheduling your injection appointment online — Somewhat convenient | 1 | 1 |
| Month 12- Scheduling your injection appointment online — Neither convenient nor inconvenient | 1 | 1 |
| Month 12- Scheduling your injection appointment online — Somewhat inconvenient | 0 | 0 |
| Month 12- Scheduling your injection appointment online — Very inconvenient | 0 | 0 |
| Month 12- A nurse coming home to give the injection — Very convenient | 3 | 2 |
| Month 12- A nurse coming home to give the injection — Somewhat convenient | 0 | 0 |
| Month 12- A nurse coming home to give the injection — Neither convenient nor inconvenient | 0 | 0 |
| Month 12- A nurse coming home to give the injection — Somewhat inconvenient | 0 | 0 |
| Month 12- A nurse coming home to give the injection — Very inconvenient | 0 | 0 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked if they would recommend telehealth services for APRETUDE to other people. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6 - I would recommend telehealth services for APRETUDE to other people. — Completely agree | 29 | 12 |
| Month 6 - I would recommend telehealth services for APRETUDE to other people. — Agree | 9 | 9 |
| Month 6 - I would recommend telehealth services for APRETUDE to other people. — Neither agree not disagree | 1 | 3 |
| Month 6 - I would recommend telehealth services for APRETUDE to other people. — Disagree | 1 | 0 |
| Month 6 - I would recommend telehealth services for APRETUDE to other people. — Completely disagree | 0 | 0 |
| Month 6 - I would recommend telehealth services for APRETUDE to other people. — Missing | 1 | 0 |
| Month 12 - I would recommend telehealth services for APRETUDE to other people. — Completely agree | 20 | 20 |
| Month 12 - I would recommend telehealth services for APRETUDE to other people. — Agree | 7 | 2 |
| Month 12 - I would recommend telehealth services for APRETUDE to other people. — Neither agree not disagree | 2 | 3 |
| Month 12 - I would recommend telehealth services for APRETUDE to other people. — Disagree | 0 | 0 |
| Month 12 - I would recommend telehealth services for APRETUDE to other people. — Completely disagree | 0 | 0 |
| Month 12 - I would recommend telehealth services for APRETUDE to other people. — Missing | 0 | 0 |
The FIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6 compared to BL | 0.08 ± 0.65 | 0.25 ± 1.23 |
| Month 12 compared to BL | -0.35 ± 0.78 | 0.17 ± 1.21 |
The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6 compared to BL | 0.09 ± 0.64 | 0.26 ± 1.26 |
| Month 12 compared to BL | -0.39 ± 0.92 | 0.21 ± 1.11 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.
| Percentage of participants | DI- PSP | RI- PSP |
|---|---|---|
| Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months? - YES | -40.1 | -45.8 |
| Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months? - NO | 35.8 | 35.1 |
| Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months?-DON'T KNOW | 4.3 | 10.8 |
| Change BL to M12 - Have you used telehealth for any APRETUDE services in the last 6 months? - YES | -46.1 | -43.1 |
| Change BL to M12 - Have you used telehealth for any APRETUDE services in the last 6 months? - NO | 44.8 | 43.1 |
| Change BL to M12-Have you used telehealth for any APRETUDE services in the last 6 months?-DON'T KNOW | 1.3 | 0.0 |
Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Video consultation — Very easy | 12 | 4 |
| Video consultation — Somewhat easy | 3 | 2 |
| Video consultation — Neither easy nor difficult | 6 | 1 |
| Video consultation — Somewhat Difficult | 0 | 0 |
| Video consultation — Very Difficult | 0 | 0 |
| Video consultation — I don't use this system | 6 | 1 |
| Telephone consultation — Very easy | 14 | 2 |
| Telephone consultation — Somewhat easy | 4 | 2 |
| Telephone consultation — Neither easy nor difficult | 3 | 0 |
| Telephone consultation — Somewhat Difficult | 1 | 0 |
| Telephone consultation — Very Difficult | 0 | 0 |
| Telephone consultation — I don't use this system | 3 | 0 |
| Remote monitoring of patients — Very easy | 3 | 1 |
| Remote monitoring of patients — Somewhat easy | 5 | 0 |
| Remote monitoring of patients — Neither easy nor difficult | 2 | 1 |
| Remote monitoring of patients — Somewhat Difficult | 0 | 0 |
| Remote monitoring of patients — Very Difficult | 0 | 0 |
| Remote monitoring of patients — I don't use this system | 1 | 1 |
| Online appointment scheduling — Very easy | 3 | 3 |
| Online appointment scheduling — Somewhat easy | 2 | 0 |
| Online appointment scheduling — Neither easy nor difficult | 3 | 0 |
| Online appointment scheduling — Somewhat Difficult | 0 | 0 |
| Online appointment scheduling — Very Difficult | 0 | 0 |
| Online appointment scheduling — I don't use this system | 2 | 0 |
| Patient portal conversations: ability for patients to send messages to providers — Very easy | 13 | 7 |
| Patient portal conversations: ability for patients to send messages to providers — Somewhat easy | 4 | 0 |
| Patient portal conversations: ability for patients to send messages to providers — Neither easy nor difficult | 4 | 0 |
| Patient portal conversations: ability for patients to send messages to providers — Somewhat Difficult | 0 | 1 |
| Patient portal conversations: ability for patients to send messages to providers — Very Difficult | 0 | 0 |
| Patient portal conversations: ability for patients to send messages to providers — I don't use this system | 2 | 0 |
| At-home testing services — Very easy | 4 | 1 |
| At-home testing services — Somewhat easy | 1 | 1 |
| At-home testing services — Neither easy nor difficult | 2 | 0 |
| At-home testing services — Somewhat Difficult | 0 | 0 |
| At-home testing services — Very Difficult | 0 | 0 |
| At-home testing services — I don't use this system | 3 | 0 |
| Send and receiving patient reported outcomes questionnaires via an online system — Very easy | 3 | 1 |
| Send and receiving patient reported outcomes questionnaires via an online system — Somewhat easy | 4 | 1 |
| Send and receiving patient reported outcomes questionnaires via an online system — Neither easy nor difficult | 3 | 0 |
| Send and receiving patient reported outcomes questionnaires via an online system — Somewhat Difficult | 0 | 0 |
| Send and receiving patient reported outcomes questionnaires via an online system — Very Difficult | 0 | 0 |
| Send and receiving patient reported outcomes questionnaires via an online system — I don't use this system | 2 | 0 |
| Online prescription refills — Very easy | 14 | 6 |
| Online prescription refills — Somewhat easy | 3 | 0 |
| Online prescription refills — Neither easy nor difficult | 4 | 0 |
| Online prescription refills — Somewhat Difficult | 0 | 0 |
| Online prescription refills — Very Difficult | 0 | 0 |
| Online prescription refills — I don't use this system | 2 | 0 |
| Online portal for patients to access medical documents, such as visit summaries and test results — Very easy | 12 | 6 |
| Online portal for patients to access medical documents, such as visit summaries and test results — Somewhat easy | 6 | 0 |
| Online portal for patients to access medical documents, such as visit summaries and test results — Neither easy nor difficult | 4 | 0 |
| Online portal for patients to access medical documents, such as visit summaries and test results — Somewhat Difficult | 0 | 0 |
| Online portal for patients to access medical documents, such as visit summaries and test results — Very Difficult | 0 | 0 |
| Online portal for patients to access medical documents, such as visit summaries and test results — I don't use this system | 2 | 0 |
| Text messaging with patients about care — Very easy | 7 | 4 |
| Text messaging with patients about care — Somewhat easy | 3 | 1 |
| Text messaging with patients about care — Neither easy nor difficult | 2 | 1 |
| Text messaging with patients about care — Somewhat Difficult | 0 | 0 |
| Text messaging with patients about care — Very Difficult | 0 | 0 |
| Text messaging with patients about care — I don't use this system | 1 | 0 |
| Email reminders to patient about upcoming visits — Very easy | 10 | 3 |
| Email reminders to patient about upcoming visits — Somewhat easy | 4 | 1 |
| Email reminders to patient about upcoming visits — Neither easy nor difficult | 2 | 0 |
| Email reminders to patient about upcoming visits — Somewhat Difficult | 0 | 0 |
| Email reminders to patient about upcoming visits — Very Difficult | 0 | 0 |
| Email reminders to patient about upcoming visits — I don't use this system | 3 | 0 |
| Text reminders — Very easy | 12 | 6 |
| Text reminders — Somewhat easy | 5 | 1 |
| Text reminders — Neither easy nor difficult | 2 | 1 |
| Text reminders — Somewhat Difficult | 0 | 0 |
| Text reminders — Very Difficult | 0 | 0 |
| Text reminders — I don't use this system | 3 | 0 |
| Automated phone call reminders — Very easy | 9 | 4 |
| Automated phone call reminders — Somewhat easy | 4 | 1 |
| Automated phone call reminders — Neither easy nor difficult | 4 | 0 |
| Automated phone call reminders — Somewhat Difficult | 0 | 0 |
| Automated phone call reminders — Very Difficult | 0 | 0 |
| Automated phone call reminders — I don't use this system | 2 | 0 |
| Staff phone call reminder — Very easy | 9 | 7 |
| Staff phone call reminder — Somewhat easy | 6 | 1 |
| Staff phone call reminder — Neither easy nor difficult | 1 | 0 |
| Staff phone call reminder — Somewhat Difficult | 0 | 0 |
| Staff phone call reminder — Very Difficult | 0 | 0 |
| Staff phone call reminder — I don't use this system | 2 | 0 |
| Sending motivational reminders to help patients persist on APRETUDE — Very easy | 2 | 1 |
| Sending motivational reminders to help patients persist on APRETUDE — Somewhat easy | 0 | 0 |
| Sending motivational reminders to help patients persist on APRETUDE — Neither easy nor difficult | 0 | 0 |
| Sending motivational reminders to help patients persist on APRETUDE — Somewhat Difficult | 0 | 0 |
| Sending motivational reminders to help patients persist on APRETUDE — Very Difficult | 0 | 0 |
| Sending motivational reminders to help patients persist on APRETUDE — I don't use this system | 0 | 0 |
| Sending cabotegravir oral lead in to patient's home — Very easy | 4 | 1 |
| Sending cabotegravir oral lead in to patient's home — Somewhat easy | 1 | 0 |
| Sending cabotegravir oral lead in to patient's home — Neither easy nor difficult | 1 | 1 |
| Sending cabotegravir oral lead in to patient's home — Somewhat Difficult | 0 | 0 |
| Sending cabotegravir oral lead in to patient's home — Very Difficult | 0 | 0 |
| Sending cabotegravir oral lead in to patient's home — I don't use this system | 1 | 0 |
| Insurance/benefits verification — Very easy | 10 | 5 |
| Insurance/benefits verification — Somewhat easy | 7 | 1 |
| Insurance/benefits verification — Neither easy nor difficult | 3 | 1 |
| Insurance/benefits verification — Somewhat Difficult | 1 | 0 |
| Insurance/benefits verification — Very Difficult | 1 | 0 |
| Insurance/benefits verification — I don't use this system | 2 | 0 |
Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Telehealth Used for any service | 2 | 5 |
| Telehealth Used for APRETUDE | 1 | 5 |
| Telehealth used for things OTHER than APRETUDE, only | 1 | 0 |
| Telehealth Not Used | 2 | 12 |
| Not Asked About Telehealth | 18 | 4 |
| Telehealth used/not used- Missing | 1 | 0 |
| Telehealth DI Used | 5 | 0 |
| Teleconsultant Used | 1 | 0 |
| Online Appointment Scheduler Used | 0 | 0 |
| Reminders Used | 3 | 0 |
| Home tests Used | 0 | 0 |
| Local labs Used | 0 | 0 |
| Online portal Used | 0 | 0 |
| Home health nurses Used | 0 | 0 |
| Screenings and assessments Used | 1 | 0 |
AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-Implementation (IMP) that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Scores on a scale | DI - SSP | RI - SSP |
|---|---|---|
| AIM-INT (Baseline) | 4.69 ± 0.43 | 4.66 ± 0.48 |
| AIM-INT (Month 4) | 4.33 ± 0.68 | 4.43 ± 0.56 |
| AIM-INT (Month 12) | 4.41 ± 0.57 | 4.52 ± 0.56 |
| AIM-IMP (Baseline) | 3.97 ± 0.83 | 4.05 ± 0.76 |
| AIM-IMP (Month 4) | 3.92 ± 0.80 | 3.86 ± 0.84 |
| AIM-IMP (Month 12) | 4.09 ± 0.67 | 3.90 ± 1.08 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Baseline- Management of scheduling injection appointments during correct injection windows — Extremely concerned | 3 | 2 |
| Baseline- Management of scheduling injection appointments during correct injection windows — Moderately concerned | 5 | 4 |
| Baseline- Management of scheduling injection appointments during correct injection windows — Somewhat concerned | 13 | 2 |
| Baseline- Management of scheduling injection appointments during correct injection windows — Slightly concerned | 5 | 7 |
| Baseline- Management of scheduling injection appointments during correct injection windows — Not at all concerned | 30 | 15 |
| Baseline- Management of rescheduling appointments during correct injection windows — Extremely concerned | 4 | 2 |
| Baseline- Management of rescheduling appointments during correct injection windows — Moderately concerned | 4 | 6 |
| Baseline- Management of rescheduling appointments during correct injection windows — Somewhat concerned | 15 | 3 |
| Baseline- Management of rescheduling appointments during correct injection windows — Slightly concerned | 6 | 9 |
| Baseline- Management of rescheduling appointments during correct injection windows — Not at all concerned | 27 | 10 |
| Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Extremely concerned | 4 | 3 |
| Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Moderately concerned | 5 | 4 |
| Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Somewhat concerned | 16 | 5 |
| Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Slightly concerned | 4 | 9 |
| Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits — Not at all concerned | 27 | 9 |
| Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Extremely concerned | 5 | 5 |
| Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Moderately concerned | 5 | 5 |
| Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Somewhat concerned | 15 | 4 |
| Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Slightly concerned | 5 | 4 |
| Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) — Not at all concerned | 26 | 12 |
| Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Extremely concerned | 5 | 3 |
| Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Moderately concerned | 4 | 4 |
| Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Somewhat concerned | 11 | 4 |
| Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Slightly concerned | 9 | 5 |
| Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs — Not at all concerned | 27 | 14 |
| Month 4- Management of scheduling injection appointments during correct injection windows — Extremely concerned | 2 | 2 |
| Month 4- Management of scheduling injection appointments during correct injection windows — Moderately concerned | 5 | 0 |
| Month 4- Management of scheduling injection appointments during correct injection windows — Somewhat concerned | 6 | 2 |
| Month 4- Management of scheduling injection appointments during correct injection windows — Slightly concerned | 3 | 4 |
| Month 4- Management of scheduling injection appointments during correct injection windows — Not at all concerned | 35 | 21 |
| Month 4- Management of rescheduling appointments during correct injection windows — Extremely concerned | 2 | 2 |
| Month 4- Management of rescheduling appointments during correct injection windows — Moderately concerned | 5 | 1 |
| Month 4- Management of rescheduling appointments during correct injection windows — Somewhat concerned | 8 | 2 |
| Month 4- Management of rescheduling appointments during correct injection windows — Slightly concerned | 4 | 9 |
| Month 4- Management of rescheduling appointments during correct injection windows — Not at all concerned | 32 | 15 |
| Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Extremely concerned | 1 | 2 |
| Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Moderately concerned | 5 | 1 |
| Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Somewhat concerned | 11 | 1 |
| Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Slightly concerned | 7 | 10 |
| Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows — Not at all concerned | 27 | 15 |
| Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Extremely concerned | 3 | 2 |
| Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Moderately concerned | 7 | 2 |
| Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Somewhat concerned | 10 | 2 |
| Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Slightly concerned | 6 | 7 |
| Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) — Not at all concerned | 25 | 16 |
| Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Extremely concerned | 1 | 3 |
| Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Moderately concerned | 5 | 2 |
| Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Somewhat concerned | 15 | 1 |
| Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Slightly concerned | 5 | 3 |
| Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs — Not at all concerned | 25 | 20 |
| Month 12- Management of scheduling injection appointments every 2 months during injection windows — Extremely concerned | 0 | 1 |
| Month 12- Management of scheduling injection appointments every 2 months during injection windows — Moderately concerned | 4 | 2 |
| Month 12- Management of scheduling injection appointments every 2 months during injection windows — Somewhat concerned | 5 | 2 |
| Month 12- Management of scheduling injection appointments every 2 months during injection windows — Slightly concerned | 7 | 4 |
| Month 12- Management of scheduling injection appointments every 2 months during injection windows — Not at all concerned | 36 | 20 |
| Month 12- Management of rescheduling appointments during correct injection windows — Extremely concerned | 1 | 1 |
| Month 12- Management of rescheduling appointments during correct injection windows — Moderately concerned | 4 | 3 |
| Month 12- Management of rescheduling appointments during correct injection windows — Somewhat concerned | 8 | 1 |
| Month 12- Management of rescheduling appointments during correct injection windows — Slightly concerned | 10 | 7 |
| Month 12- Management of rescheduling appointments during correct injection windows — Not at all concerned | 29 | 17 |
| Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Extremely concerned | 2 | 1 |
| Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Moderately concerned | 3 | 2 |
| Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Somewhat concerned | 8 | 3 |
| Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Slightly concerned | 11 | 9 |
| Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits — Not at all concerned | 28 | 14 |
| Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Extremely concerned | 4 | 3 |
| Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Moderately concerned | 4 | 0 |
| Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Somewhat concerned | 8 | 5 |
| Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Slightly concerned | 10 | 9 |
| Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) — Not at all concerned | 26 | 12 |
| Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Extremely concerned | 1 | 1 |
| Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Moderately concerned | 3 | 3 |
| Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Somewhat concerned | 10 | 2 |
| Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Slightly concerned | 9 | 6 |
| Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs — Not at all concerned | 29 | 17 |
AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-IMP that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.
| Scores on a scale | DI - SSP | RI - SSP |
|---|---|---|
| AIM-INT, Month 4 compared to BL | -0.36 ± 0.66 | -0.22 ± 0.67 |
| AIM-INT, Month 12 compared to BL | -0.33 ± 0.50 | -0.11 ± 0.74 |
| AIM-IMP, Month 4 compared to BL | -0.06 ± 0.77 | -0.16 ± 0.81 |
| AIM-IMP, Month 12 compared to BL | 0.04 ± 0.84 | -0.20 ± 1.24 |
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE (Item \[I\]1= Management of scheduling injection appointments during correct injection windows, I2= Management of rescheduling appointments during correct injection windows, I3= Ability to schedule/reschedule patients who missed APRETUDE visits, I4= Ability to identify and flag missed injection visits to providers (in a timely manner), I5= Ability to manage patients presenting to APRETUDE appointments with other care needs). Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.
| Percentage of participants | DI - SSP | RI - SSP |
|---|---|---|
| Change BL to M4 - I1: Extremely concerned | -1.4 | 0.2 |
| Change BL to M4 - I1: Moderately concerned | 0.9 | -13.3 |
| Change BL to M4 - I1: Somewhat concerned | -11.4 | 0.2 |
| Change BL to M4 - I1: Slightly concerned | -3.0 | -9.5 |
| Change BL to M4 - I1: Not at all concerned | 15.1 | 22.4 |
| Change BL to M4 - I2: Extremely concerned | -3.2 | 0.2 |
| Change BL to M4 - I2: Moderately concerned | 2.7 | -16.6 |
| Change BL to M4 - I2: Somewhat concerned | -11.1 | -3.1 |
| Change BL to M4 - I2: Slightly concerned | -2.9 | 1.0 |
| Change BL to M4 - I2: Not at all concerned | 14.5 | 18.4 |
| Change BL to M4 - I3: Extremely concerned | -5.2 | -3.1 |
| Change BL to M4 - I3: Moderately concerned | 0.9 | -9.9 |
| Change BL to M4 - I3: Somewhat concerned | -7.0 | -13.2 |
| Change BL to M4 - I3: Slightly concerned | 6.6 | 4.5 |
| Change BL to M4 - I3: Not at all concerned | 4.7 | 21.7 |
| Change BL to M4 - I4: Extremely concerned | -3.0 | -9.8 |
| Change BL to M4 - I4: Moderately concerned | 4.8 | -9.8 |
| Change BL to M4 - I4: Somewhat concerned | -7.2 | -6.4 |
| Change BL to M4 - I4: Slightly concerned | 2.8 | 10.8 |
| Change BL to M4 - I4: Not at all concerned | 2.6 | 15.2 |
| Change BL to M4 - I5: Extremely concerned | -7.0 | 0.3 |
| Change BL to M4 - I5: Moderately concerned | 2.7 | -6.4 |
| Change BL to M4 - I5: Somewhat concerned | 9.8 | -9.9 |
| Change BL to M4 - I5: Slightly concerned | -6.3 | -6.3 |
| Change BL to M4 - I5: Not at all concerned | 0.8 | 22.3 |
| Change BL to M12 - I1: Extremely concerned | -5.4 | -3.2 |
| Change BL to M12 - I1: Moderately concerned | -1.2 | -6.4 |
| Change BL to M12 - I1: Somewhat concerned | -13.6 | 0.2 |
| Change BL to M12 - I1: Slightly concerned | 4.5 | -9.5 |
| Change BL to M12 - I1: Not at all concerned | 15.7 | 19.0 |
| Change BL to M12 - I2: Extremely concerned | -5.2 | -3.2 |
| Change BL to M12 - I2: Moderately concerned | 0.5 | -9.7 |
| Change BL to M12 - I2: Somewhat concerned | -11.4 | -6.6 |
| Change BL to M12 - I2: Slightly concerned | 8.5 | -5.9 |
| Change BL to M12 - I2: Not at all concerned | 7.6 | 25.3 |
| Change BL to M12 - I3: Extremely concerned | -3.3 | -6.6 |
| Change BL to M12 - I3: Moderately concerned | -3.2 | -6.4 |
| Change BL to M12 - I3: Somewhat concerned | -13.2 | -6.3 |
| Change BL to M12 - I3: Slightly concerned | 14.0 | 1.0 |
| Change BL to M12 - I3: Not at all concerned | 5.6 | 18.3 |
| Change BL to M12 - I4: Extremely concerned | -1.2 | -6.3 |
| Change BL to M12 - I4: Moderately concerned | -1.2 | -16.7 |
| Change BL to M12 - I4: Somewhat concerned | -11.4 | 3.9 |
| Change BL to M12 - I4: Slightly concerned | 10.3 | 17.7 |
| Change BL to M12 - I4: Not at all concerned | 3.6 | 1.4 |
| Change BL to M12 - I5: Extremely concerned | -7.0 | -6.6 |
| Change BL to M12 - I5: Moderately concerned | -1.4 | -3.0 |
| Change BL to M12 - I5: Somewhat concerned | -0.4 | -6.4 |
| Change BL to M12 - I5: Slightly concerned | 1.2 | 4.0 |
| Change BL to M12 - I5: Not at all concerned | 7.6 | 12.0 |
The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Baseline | 4.46 ± 0.69 | 4.41 ± 0.68 |
| Month 6 | 4.57 ± 0.64 | 4.57 ± 0.55 |
| Month 12 | 4.61 ± 0.63 | 4.60 ± 0.67 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE.
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Very helpful | 35 | 32 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Helpful | 27 | 23 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Somewhat helpful | 12 | 10 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — A little helpful | 7 | 2 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Not at all helpful | 1 | 2 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Did not use it | 23 | 6 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Missing | 12 | 9 |
| Patient Brochure that helps understand the process of receiving APRETUDE injections — Very helpful | 37 | 30 |
| Patient Brochure that helps understand the process of receiving APRETUDE injections — Helpful | 27 | 25 |
| Patient Brochure that helps understand the process of receiving APRETUDE injections — Somewhat helpful | 11 | 10 |
| Patient Brochure that helps understand the process of receiving APRETUDE injections — A little helpful | 5 | 3 |
| Patient Brochure that helps understand the process of receiving APRETUDE injections — Not at all helpful | 1 | 0 |
| Patient Brochure that helps understand the process of receiving APRETUDE injections — Did not use it | 24 | 7 |
| Patient Brochure that helps understand the process of receiving APRETUDE injections — Missing | 12 | 9 |
| Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Very helpful | 32 | 0 |
| Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Helpful | 25 | 0 |
| Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Somewhat helpful | 8 | 0 |
| Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — A little helpful | 7 | 0 |
| Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Not at all helpful | 1 | 0 |
| Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Did not use it | 32 | 0 |
| Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) — Missing | 12 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Very helpful | 30 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Helpful | 22 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Somewhat helpful | 8 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — A little helpful | 6 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Not at all helpful | 1 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Did not use it | 38 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Missing | 12 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Very helpful | 30 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Helpful | 25 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Somewhat helpful | 7 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — A little helpful | 5 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Not at all helpful | 0 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Did not use it | 38 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Missing | 12 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Very helpful | 26 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Helpful | 23 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Somewhat helpful | 9 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — A little helpful | 6 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Not at all helpful | 0 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Did not use it | 41 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Missing | 12 | 0 |
| The study website to access APRETDUE information (RI) — Very helpful | 0 | 28 |
| The study website to access APRETDUE information (RI) — Helpful | 0 | 19 |
| The study website to access APRETDUE information (RI) — Somewhat helpful | 0 | 13 |
| The study website to access APRETDUE information (RI) — A little helpful | 0 | 4 |
| The study website to access APRETDUE information (RI) — Not at all helpful | 0 | 0 |
| The study website to access APRETDUE information (RI) — Did not use it | 0 | 11 |
| The study website to access APRETDUE information (RI) — Missing | 0 | 9 |
| The study app to access APRETUDE information (DI) — Very helpful | 23 | 0 |
| The study app to access APRETUDE information (DI) — Helpful | 22 | 0 |
| The study app to access APRETUDE information (DI) — Somewhat helpful | 12 | 0 |
| The study app to access APRETUDE information (DI) — A little helpful | 6 | 0 |
| The study app to access APRETUDE information (DI) — Not at all helpful | 0 | 0 |
| The study app to access APRETUDE information (DI) — Did not use it | 42 | 0 |
| The study app to access APRETUDE information (DI) — Missing | 12 | 0 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M6 (equivalent to M7 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Very helpful | 28 | 24 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Helpful | 17 | 17 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Somewhat helpful | 18 | 6 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — A little helpful | 3 | 0 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Not at all helpful | 1 | 0 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Did not receive/Did not use it | 25 | 16 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Missing | 25 | 21 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Very helpful | 29 | 21 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Helpful | 17 | 18 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Somewhat helpful | 14 | 7 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — A little helpful | 2 | 1 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Not at all helpful | 1 | 0 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Did not receive/Did not use it | 29 | 16 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Missing | 25 | 21 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Very helpful | 27 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Helpful | 19 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Somewhat helpful | 8 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — A little helpful | 5 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Not at all helpful | 1 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Did not receive/Did not use it | 32 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Missing | 25 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Very helpful | 23 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Helpful | 20 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Somewhat helpful | 8 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — A little helpful | 5 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Not at all helpful | 2 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Did not receive/Did not use it | 34 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Missing | 25 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Very helpful | 26 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Helpful | 16 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Somewhat helpful | 9 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — A little helpful | 4 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Not at all helpful | 1 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Did not receive/Did not use it | 36 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Missing | 25 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Very helpful | 22 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Helpful | 15 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Somewhat helpful | 10 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — A little helpful | 6 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Not at all helpful | 1 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Did not receive/Did not use it | 38 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Missing | 25 | 0 |
| The study website to access APRETDUE information (RI) — Very helpful | 0 | 21 |
| The study website to access APRETDUE information (RI) — Helpful | 0 | 16 |
| The study website to access APRETDUE information (RI) — Somewhat helpful | 0 | 8 |
| The study website to access APRETDUE information (RI) — A little helpful | 0 | 2 |
| The study website to access APRETDUE information (RI) — Not at all helpful | 0 | 1 |
| The study website to access APRETDUE information (RI) — Did not receive/Did not use it | 0 | 15 |
| The study website to access APRETDUE information (RI) — Missing | 0 | 21 |
| The study app to access APRETUDE information (DI) — Very helpful | 24 | 0 |
| The study app to access APRETUDE information (DI) — Helpful | 17 | 0 |
| The study app to access APRETUDE information (DI) — Somewhat helpful | 15 | 0 |
| The study app to access APRETUDE information (DI) — A little helpful | 8 | 0 |
| The study app to access APRETUDE information (DI) — Not at all helpful | 5 | 0 |
| The study app to access APRETUDE information (DI) — Did not receive/Did not use it | 23 | 0 |
| The study app to access APRETUDE information (DI) — Missing | 25 | 0 |
| Important safety information document details safety information relating to APRETUDE — Very helpful | 26 | 19 |
| Important safety information document details safety information relating to APRETUDE — Helpful | 17 | 18 |
| Important safety information document details safety information relating to APRETUDE — Somewhat helpful | 11 | 9 |
| Important safety information document details safety information relating to APRETUDE — A little helpful | 8 | 0 |
| Important safety information document details safety information relating to APRETUDE — Not at all helpful | 2 | 1 |
| Important safety information document details safety information relating to APRETUDE — Did not receive/Did not use it | 28 | 16 |
| Important safety information document details safety information relating to APRETUDE — Missing | 25 | 21 |
| Important facts document details important facts relating to APRETUDE — Very helpful | 26 | 19 |
| Important facts document details important facts relating to APRETUDE — Helpful | 19 | 17 |
| Important facts document details important facts relating to APRETUDE — Somewhat helpful | 10 | 9 |
| Important facts document details important facts relating to APRETUDE — A little helpful | 4 | 1 |
| Important facts document details important facts relating to APRETUDE — Not at all helpful | 1 | 1 |
| Important facts document details important facts relating to APRETUDE — Did not receive/Did not use it | 32 | 16 |
| Important facts document details important facts relating to APRETUDE — Missing | 25 | 21 |
| A flyer on PrEP options (DI) — Very helpful | 22 | 0 |
| A flyer on PrEP options (DI) — Helpful | 16 | 0 |
| A flyer on PrEP options (DI) — Somewhat helpful | 9 | 0 |
| A flyer on PrEP options (DI) — A little helpful | 2 | 0 |
| A flyer on PrEP options (DI) — Not at all helpful | 2 | 0 |
| A flyer on PrEP options (DI) — Did not receive/Did not use it | 41 | 0 |
| A flyer on PrEP options (DI) — Missing | 25 | 0 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Very helpful | 23 | 24 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Helpful | 26 | 14 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Somewhat helpful | 5 | 8 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — A little helpful | 5 | 2 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Not at all helpful | 0 | 2 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Did not receive/Did not use it | 18 | 13 |
| Getting Started Brochure that gives an overview of how to get started with APRETUDE — Missing | 40 | 21 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Very helpful | 22 | 22 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Helpful | 27 | 14 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Somewhat helpful | 6 | 10 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — A little helpful | 4 | 3 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Not at all helpful | 0 | 1 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Did not receive/Did not use it | 18 | 13 |
| Patient Brochure helps understand the process of receiving APRETUDE injections — Missing | 40 | 21 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Very helpful | 25 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Helpful | 20 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Somewhat helpful | 6 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — A little helpful | 5 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Not at all helpful | 0 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Did not receive/Did not use it | 21 | 0 |
| Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) — Missing | 40 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Very helpful | 25 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Helpful | 18 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Somewhat helpful | 7 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — A little helpful | 3 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Not at all helpful | 0 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Did not receive/Did not use it | 24 | 0 |
| The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) — Missing | 40 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Very helpful | 26 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Helpful | 17 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Somewhat helpful | 6 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — A little helpful | 5 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Not at all helpful | 0 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Did not receive/Did not use it | 23 | 0 |
| The What to Expect video which shows what to expect during the APRETUDE process (DI) — Missing | 40 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Very helpful | 22 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Helpful | 20 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Somewhat helpful | 8 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — A little helpful | 3 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Not at all helpful | 0 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Did not receive/Did not use it | 24 | 0 |
| The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) — Missing | 40 | 0 |
| The study website to access APRETDUE information (RI) — Very helpful | 0 | 19 |
| The study website to access APRETDUE information (RI) — Helpful | 0 | 16 |
| The study website to access APRETDUE information (RI) — Somewhat helpful | 0 | 7 |
| The study website to access APRETDUE information (RI) — A little helpful | 0 | 7 |
| The study website to access APRETDUE information (RI) — Not at all helpful | 0 | 1 |
| The study website to access APRETDUE information (RI) — Did not receive/Did not use it | 0 | 13 |
| The study website to access APRETDUE information (RI) — Missing | 0 | 21 |
| The study app/website to access APRETUDE information - the Pillar Spot (DI) — Very helpful | 22 | 0 |
| The study app/website to access APRETUDE information - the Pillar Spot (DI) — Helpful | 19 | 0 |
| The study app/website to access APRETUDE information - the Pillar Spot (DI) — Somewhat helpful | 9 | 0 |
| The study app/website to access APRETUDE information - the Pillar Spot (DI) — A little helpful | 8 | 0 |
| The study app/website to access APRETUDE information - the Pillar Spot (DI) — Not at all helpful | 1 | 0 |
| The study app/website to access APRETUDE information - the Pillar Spot (DI) — Did not receive/Did not use it | 18 | 0 |
| The study app/website to access APRETUDE information - the Pillar Spot (DI) — Missing | 40 | 0 |
| Important safety information document details safety information relating to APRETUDE — Very helpful | 22 | 19 |
| Important safety information document details safety information relating to APRETUDE — Helpful | 22 | 17 |
| Important safety information document details safety information relating to APRETUDE — Somewhat helpful | 9 | 9 |
| Important safety information document details safety information relating to APRETUDE — A little helpful | 2 | 5 |
| Important safety information document details safety information relating to APRETUDE — Not at all helpful | 0 | 1 |
| Important safety information document details safety information relating to APRETUDE — Did not receive/Did not use it | 22 | 12 |
| Important safety information document details safety information relating to APRETUDE — Missing | 40 | 21 |
| Important facts document details important facts relating to APRETUDE — Very helpful | 21 | 20 |
| Important facts document details important facts relating to APRETUDE — Helpful | 23 | 16 |
| Important facts document details important facts relating to APRETUDE — Somewhat helpful | 8 | 7 |
| Important facts document details important facts relating to APRETUDE — A little helpful | 1 | 6 |
| Important facts document details important facts relating to APRETUDE — Not at all helpful | 0 | 1 |
| Important facts document details important facts relating to APRETUDE — Did not receive/Did not use it | 24 | 13 |
| Important facts document details important facts relating to APRETUDE — Missing | 40 | 21 |
| A flyer on PrEP options — Very helpful | 22 | 19 |
| A flyer on PrEP options — Helpful | 17 | 14 |
| A flyer on PrEP options — Somewhat helpful | 8 | 7 |
| A flyer on PrEP options — A little helpful | 2 | 5 |
| A flyer on PrEP options — Not at all helpful | 1 | 1 |
| A flyer on PrEP options — Did not receive/Did not use it | 27 | 17 |
| A flyer on PrEP options — Missing | 40 | 21 |
This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.
| Scores on a scale | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Month 6 compared to BL | 0.17 ± 0.66 | 0.20 ± 0.72 |
| Month 12 compared to BL | 0.27 ± 0.63 | 0.19 ± 0.87 |
In this outcome measure, usong the ISQ, PSPs were asked about the helpfulness of various knowledge materials (I1= Getting Started Brochure that gives an overview of how to get started with APRETUDE, I2 = Patient Brochure helps understand the process of receiving APRETUDE, I3 = HIV \& PrEP video gives key facts about HIV and PrEP options (DI), I4 = APRETUDE Myths and Facts video, addressing common myths about APRETUDE (DI), I5 = The What to Expect video which shows what to expect during the APRETUDE process (DI), I6 = The ViiV Connect program Video and frequently asked questions (DI), I7 = The study website to access APRETDUE information (RI), I8 = The study app to access APRETUDE information (DI). Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.
| Percentage of participants | DI - PSP | RI - PSP |
|---|---|---|
| Change BL to M6 - I1: Very helpful | -2.9 | -4.6 |
| Change BL to M6 - I1: Helpful | -7.2 | -3.7 |
| Change BL to M6 - I1: Somewhat helpful | 8.1 | -3.8 |
| Change BL to M6 - I1: A little helpful | -3.4 | -2.7 |
| Change BL to M6 - I1: Not at all helpful | 0.1 | -2.7 |
| Change BL to M6 - I1: I did not use it | 5.3 | 17.4 |
| Change BL to M6 - I2: Very helpful | -3.7 | -6.7 |
| Change BL to M6 - I2: Helpful | -7.2 | -4.8 |
| Change BL to M6 - I2: Somewhat helpful | 4.7 | -2.2 |
| Change BL to M6 - I2: A little helpful | -2.6 | -2.4 |
| Change BL to M6 - I2: Not at all helpful | 0.1 | 0.0 |
| Change BL to M6 - I2: I did not use it | 8.7 | 16.1 |
| Change BL to M6 - I3: Very helpful | -1.1 | — |
| Change BL to M6 - I3: Helpful | -3.2 | — |
| Change BL to M6 - I3: Somewhat helpful | 1.1 | — |
| Change BL to M6 - I3: A little helpful | -1.2 | — |
| Change BL to M6 - I3: Not at all helpful | 0.1 | — |
| Change BL to M6 - I3: I did not use it | 4.3 | — |
| Change BL to M6 - I4: Very helpful | -3.6 | — |
| Change BL to M6 - I4: Helpful | 0.8 | — |
| Change BL to M6 - I4: Somewhat helpful | 1.1 | — |
| Change BL to M6 - I4: A little helpful | -0.3 | — |
| Change BL to M6 - I4: Not at all helpful | 1.2 | — |
| Change BL to M6 - I4: I did not use it | 0.8 | — |
| Change BL to M6 - I5: Very helpful | -0.3 | — |
| Change BL to M6 - I5: Helpful | -6.4 | — |
| Change BL to M6 - I5: Somewhat helpful | 3.1 | — |
| Change BL to M6 - I5: A little helpful | -0.4 | — |
| Change BL to M6 - I5: Not at all helpful | 1.1 | — |
| Change BL to M6 - I5: I did not use it | 2.9 | — |
| Change BL to M6 - I6: Very helpful | -0.8 | — |
| Change BL to M6 - I6: Helpful | -5.6 | — |
| Change BL to M6 - I6: Somewhat helpful | 2.3 | — |
| Change BL to M6 - I6: A little helpful | 0.8 | — |
| Change BL to M6 - I6: Not at all helpful | 1.1 | — |
| Change BL to M6 - I6: I did not use it | 2.3 | — |
| Change BL to M6 - I7: Very helpful | — | -4.0 |
| Change BL to M6 - I7: Helpful | — | 0.1 |
| Change BL to M6 - I7: Somewhat helpful | — | -4.6 |
| Change BL to M6 - I7: A little helpful | — | -2.2 |
| Change BL to M6 - I7: Not at all helpful | — | 1.6 |
| Change BL to M6 - I7: I did not use it | — | 9.1 |
| Change BL to M6 - I8: Very helpful | 4.2 | — |
| Change BL to M6 - I8: Helpful | -2.5 | — |
| Change BL to M6 - I8: Somewhat helpful | 4.9 | — |
| Change BL to M6 - I8: A little helpful | 3.0 | — |
| Change BL to M6 - I8: Not at all helpful | 5.4 | — |
| Change BL to M6 - I8: I did not use it | -15.0 | — |
| Change BL to M12 - I1: Very helpful | -3.5 | -4.6 |
| Change BL to M12 - I1: Helpful | 8.1 | -8.4 |
| Change BL to M12 - I1: Somewhat helpful | -4.9 | -0.6 |
| Change BL to M12 - I1: A little helpful | -0.2 | 0.5 |
| Change BL to M12 - I1: Not at all helpful | -1.0 | 0.5 |
| Change BL to M12 - I1: I did not use it | 1.5 | 12.6 |
| Change BL to M12 - I2: Very helpful | -6.7 | -5.1 |
| Change BL to M12 - I2: Helpful | 9.4 | -11.1 |
| Change BL to M12 - I2: Somewhat helpful | -2.7 | 2.5 |
| Change BL to M12 - I2: A little helpful | 0.4 | 0.8 |
| Change BL to M12 - I2: Not at all helpful | -1.0 | 1.6 |
| Change BL to M12 - I2: I did not use it | 0.5 | 11.3 |
| Change BL to M12 - I3: Very helpful | 2.0 | — |
| Change BL to M12 - I3: Helpful | 2.2 | — |
| Change BL to M12 - I3: Somewhat helpful | 0.2 | — |
| Change BL to M12 - I3: A little helpful | -0.2 | — |
| Change BL to M12 - I3: Not at all helpful | -1.0 | — |
| Change BL to M12 - I3: I did not use it | -3.2 | — |
| Change BL to M12 - I4: Very helpful | 3.9 | — |
| Change BL to M12 - I4: Helpful | 2.4 | — |
| Change BL to M12 - I4: Somewhat helpful | 1.5 | — |
| Change BL to M12 - I4: A little helpful | -1.8 | — |
| Change BL to M12 - I4: Not at all helpful | -1.0 | — |
| Change BL to M12 - I4: I did not use it | -5.0 | — |
| Change BL to M12 - I5: Very helpful | 5.2 | — |
| Change BL to M12 - I5: Helpful | -1.7 | — |
| Change BL to M12 - I5: Somewhat helpful | 1.1 | — |
| Change BL to M12 - I5: A little helpful | 1.7 | — |
| Change BL to M12 - I5: Not at all helpful | 0.0 | — |
| Change BL to M12 - I5: I did not use it | -6.3 | — |
| Change BL to M12 - I6: Very helpful | 3.8 | — |
| Change BL to M12 - I6: Helpful | 4.1 | — |
| Change BL to M12 - I6: Somewhat helpful | 1.8 | — |
| Change BL to M12 - I6: A little helpful | -1.8 | — |
| Change BL to M12 - I6: Not at all helpful | 0.0 | — |
| Change BL to M12 - I6: I did not use it | -7.9 | — |
| Change BL to M12 - I7: Very helpful | — | -7.2 |
| Change BL to M12 - I7: Helpful | — | 0.1 |
| Change BL to M12 - I7: Somewhat helpful | — | -6.2 |
| Change BL to M12 - I7: A little helpful | — | 5.8 |
| Change BL to M12 - I7: Not at all helpful | — | 1.6 |
| Change BL to M12 - I7: I did not use it | — | 6.0 |
| Change BL to M12 - I8: Very helpful | 6.7 | — |
| Change BL to M12 - I8: Helpful | 3.7 | — |
| Change BL to M12 - I8: Somewhat helpful | 0.3 | — |
| Change BL to M12 - I8: A little helpful | 4.7 | — |
| Change BL to M12 - I8: Not at all helpful | 1.3 | — |
| Change BL to M12 - I8: I did not use it | -16.6 | — |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the usefulness of various implementation strategies used for implementing APRETUDE in their clinic/practice. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Frequently Asked Questions Brochure — Not at all useful | 1 | 0 |
| Frequently Asked Questions Brochure — A little useful | 3 | 1 |
| Frequently Asked Questions Brochure — Somewhat useful | 5 | 1 |
| Frequently Asked Questions Brochure — Useful | 5 | 8 |
| Frequently Asked Questions Brochure — Very Useful | 5 | 2 |
| Readiness Consideration — Not at all useful | 0 | 0 |
| Readiness Consideration — A little useful | 2 | 0 |
| Readiness Consideration — Somewhat useful | 3 | 2 |
| Readiness Consideration — Useful | 5 | 7 |
| Readiness Consideration — Very Useful | 6 | 2 |
| Get Started Overview-Init/Adm Guide — Not at all useful | 0 | 0 |
| Get Started Overview-Init/Adm Guide — A little useful | 3 | 0 |
| Get Started Overview-Init/Adm Guide — Somewhat useful | 4 | 2 |
| Get Started Overview-Init/Adm Guide — Useful | 6 | 7 |
| Get Started Overview-Init/Adm Guide — Very Useful | 6 | 2 |
| Injection Education Video — Not at all useful | 0 | 0 |
| Injection Education Video — A little useful | 0 | 0 |
| Injection Education Video — Somewhat useful | 5 | 5 |
| Injection Education Video — Useful | 8 | 7 |
| Injection Education Video — Very Useful | 15 | 6 |
| Provider Website- location where all materials and videos on APRETUDE are located (RI) — Not at all useful | 0 | 2 |
| Provider Website- location where all materials and videos on APRETUDE are located (RI) — A little useful | 0 | 0 |
| Provider Website- location where all materials and videos on APRETUDE are located (RI) — Somewhat useful | 0 | 2 |
| Provider Website- location where all materials and videos on APRETUDE are located (RI) — Useful | 0 | 8 |
| Provider Website- location where all materials and videos on APRETUDE are located (RI) — Very Useful | 0 | 1 |
| Patient Materials — Not at all useful | 0 | 0 |
| Patient Materials — A little useful | 3 | 0 |
| Patient Materials — Somewhat useful | 3 | 2 |
| Patient Materials — Useful | 7 | 10 |
| Patient Materials — Very Useful | 8 | 3 |
| Implementation Guidance Video (DI) — Not at all useful | 0 | 0 |
| Implementation Guidance Video (DI) — A little useful | 2 | 0 |
| Implementation Guidance Video (DI) — Somewhat useful | 2 | 0 |
| Implementation Guidance Video (DI) — Useful | 9 | 0 |
| Implementation Guidance Video (DI) — Very Useful | 4 | 0 |
| Appointment Scheduler — Not at all useful | 1 | 0 |
| Appointment Scheduler — A little useful | 0 | 0 |
| Appointment Scheduler — Somewhat useful | 2 | 0 |
| Appointment Scheduler — Useful | 6 | 5 |
| Appointment Scheduler — Very Useful | 6 | 2 |
| Pre-scheduled Appointment Guidance (DI) — Not at all useful | 0 | 0 |
| Pre-scheduled Appointment Guidance (DI) — A little useful | 0 | 0 |
| Pre-scheduled Appointment Guidance (DI) — Somewhat useful | 3 | 0 |
| Pre-scheduled Appointment Guidance (DI) — Useful | 6 | 0 |
| Pre-scheduled Appointment Guidance (DI) — Very Useful | 6 | 0 |
| Designated Injection Days Guidance (DI) — Not at all useful | 0 | 0 |
| Designated Injection Days Guidance (DI) — A little useful | 1 | 0 |
| Designated Injection Days Guidance (DI) — Somewhat useful | 5 | 0 |
| Designated Injection Days Guidance (DI) — Useful | 7 | 0 |
| Designated Injection Days Guidance (DI) — Very Useful | 2 | 0 |
| Drop-in Injection Visits Guidance (DI) — Not at all useful | 0 | 0 |
| Drop-in Injection Visits Guidance (DI) — A little useful | 0 | 0 |
| Drop-in Injection Visits Guidance (DI) — Somewhat useful | 4 | 0 |
| Drop-in Injection Visits Guidance (DI) — Useful | 4 | 0 |
| Drop-in Injection Visits Guidance (DI) — Very Useful | 4 | 0 |
| Transport Support to Patient Appt (DI) — Not at all useful | 0 | 0 |
| Transport Support to Patient Appt (DI) — A little useful | 0 | 0 |
| Transport Support to Patient Appt (DI) — Somewhat useful | 4 | 0 |
| Transport Support to Patient Appt (DI) — Useful | 5 | 0 |
| Transport Support to Patient Appt (DI) — Very Useful | 11 | 0 |
| Monthly Implement Facilitation Call (DI) — Not at all useful | 2 | 0 |
| Monthly Implement Facilitation Call (DI) — A little useful | 0 | 0 |
| Monthly Implement Facilitation Call (DI) — Somewhat useful | 5 | 0 |
| Monthly Implement Facilitation Call (DI) — Useful | 9 | 0 |
| Monthly Implement Facilitation Call (DI) — Very Useful | 8 | 0 |
| Group Implement Facilitation Calls (DI) — Not at all useful | 1 | 0 |
| Group Implement Facilitation Calls (DI) — A little useful | 1 | 0 |
| Group Implement Facilitation Calls (DI) — Somewhat useful | 5 | 0 |
| Group Implement Facilitation Calls (DI) — Useful | 8 | 0 |
| Group Implement Facilitation Calls (DI) — Very Useful | 9 | 0 |
| Document on How Discuss Sex Health (DI) — Not at all useful | 0 | 0 |
| Document on How Discuss Sex Health (DI) — A little useful | 1 | 0 |
| Document on How Discuss Sex Health (DI) — Somewhat useful | 3 | 0 |
| Document on How Discuss Sex Health (DI) — Useful | 6 | 0 |
| Document on How Discuss Sex Health (DI) — Very Useful | 4 | 0 |
| PILLAR Spot (DI) — Not at all useful | 1 | 0 |
| PILLAR Spot (DI) — A little useful | 3 | 0 |
| PILLAR Spot (DI) — Somewhat useful | 7 | 0 |
| PILLAR Spot (DI) — Useful | 13 | 0 |
| PILLAR Spot (DI) — Very Useful | 10 | 0 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how useful various implementation strategies have been in supporting them while taking APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Brochures and other print materials to educate you on APRETUDE — Not at all useful | 1 | 0 |
| Brochures and other print materials to educate you on APRETUDE — Not very useful | 2 | 1 |
| Brochures and other print materials to educate you on APRETUDE — Somewhat useful | 10 | 10 |
| Brochures and other print materials to educate you on APRETUDE — Useful | 23 | 12 |
| Brochures and other print materials to educate you on APRETUDE — Extremely useful | 13 | 12 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Not at all useful | 1 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Not very useful | 1 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Somewhat useful | 8 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Useful | 21 | 0 |
| Videos to educate you on HIV, PrEP, APRETUDE materials (DI) — Extremely useful | 9 | 0 |
| A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Not at all useful | 2 | 0 |
| A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Not very useful | 0 | 0 |
| A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Somewhat useful | 3 | 0 |
| A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Useful | 6 | 0 |
| A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) — Extremely useful | 4 | 0 |
| Reminders about injections — Not at all useful | 3 | 0 |
| Reminders about injections — Not very useful | 2 | 0 |
| Reminders about injections — Somewhat useful | 5 | 3 |
| Reminders about injections — Useful | 25 | 22 |
| Reminders about injections — Extremely useful | 30 | 26 |
| Having video or telephone appointments with your doctor — Not at all useful | 1 | 0 |
| Having video or telephone appointments with your doctor — Not very useful | 0 | 0 |
| Having video or telephone appointments with your doctor — Somewhat useful | 3 | 1 |
| Having video or telephone appointments with your doctor — Useful | 7 | 7 |
| Having video or telephone appointments with your doctor — Extremely useful | 6 | 8 |
| Sending chats or texts to your doctor on the Pillar Spot (DI) — Not at all useful | 1 | 0 |
| Sending chats or texts to your doctor on the Pillar Spot (DI) — Not very useful | 0 | 0 |
| Sending chats or texts to your doctor on the Pillar Spot (DI) — Somewhat useful | 3 | 0 |
| Sending chats or texts to your doctor on the Pillar Spot (DI) — Useful | 11 | 0 |
| Sending chats or texts to your doctor on the Pillar Spot (DI) — Extremely useful | 8 | 0 |
| Having a nurse come home to conduct your HIV test (DI) — Not at all useful | 1 | 0 |
| Having a nurse come home to conduct your HIV test (DI) — Not very useful | 0 | 0 |
| Having a nurse come home to conduct your HIV test (DI) — Somewhat useful | 1 | 0 |
| Having a nurse come home to conduct your HIV test (DI) — Useful | 2 | 0 |
| Having a nurse come home to conduct your HIV test (DI) — Extremely useful | 1 | 0 |
| Having a nurse come home to give your injection (DI) — Not at all useful | 1 | 0 |
| Having a nurse come home to give your injection (DI) — Not very useful | 0 | 0 |
| Having a nurse come home to give your injection (DI) — Somewhat useful | 1 | 0 |
| Having a nurse come home to give your injection (DI) — Useful | 2 | 0 |
| Having a nurse come home to give your injection (DI) — Extremely useful | 1 | 0 |
| Receiving transportation to the clinic/doctor's office for your injection (DI) — Not at all useful | 1 | 0 |
| Receiving transportation to the clinic/doctor's office for your injection (DI) — Not very useful | 0 | 0 |
| Receiving transportation to the clinic/doctor's office for your injection (DI) — Somewhat useful | 2 | 0 |
| Receiving transportation to the clinic/doctor's office for your injection (DI) — Useful | 4 | 0 |
| Receiving transportation to the clinic/doctor's office for your injection (DI) — Extremely useful | 15 | 0 |
| A website/app to access APRETUDE information- the Pillar Spot (DI) — Not at all useful | 2 | 0 |
| A website/app to access APRETUDE information- the Pillar Spot (DI) — Not very useful | 1 | 0 |
| A website/app to access APRETUDE information- the Pillar Spot (DI) — Somewhat useful | 8 | 0 |
| A website/app to access APRETUDE information- the Pillar Spot (DI) — Useful | 14 | 0 |
| A website/app to access APRETUDE information- the Pillar Spot (DI) — Extremely useful | 7 | 0 |
| The website to access APRETUDE information (RI) — Not at all useful | 0 | 1 |
| The website to access APRETUDE information (RI) — Not very useful | 0 | 1 |
| The website to access APRETUDE information (RI) — Somewhat useful | 0 | 6 |
| The website to access APRETUDE information (RI) — Useful | 0 | 11 |
| The website to access APRETUDE information (RI) — Extremely useful | 0 | 6 |
Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs provided their insights on the tools and strategies used for implementing APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Medication Administration Planner | 7 | 4 |
| Frequently Asked Questions (FAQs) | 11 | 8 |
| Readiness Considerations | 4 | 4 |
| Getting Started Overview | 4 | 11 |
| Injection Education Video | 13 | 10 |
| Drop-in visits (DI) | 11 | 0 |
| Designated injection days (DI) | 5 | 0 |
| Prescheduled Appointments (DI) | 18 | 0 |
| Transportation services (DI) | 10 | 0 |
| PrEP Communication Options Tool (DI) | 8 | 0 |
| Implementation guidance video (DI) | 10 | 0 |
| How to discuss sexual health guidance (DI) | 3 | 0 |
| Acquisition Tracker (DI) | 1 | 0 |
Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, PSPs provided their insights regarding the tools and strategies used for delivering APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Getting Started brochure | 10 | 9 |
| Participant handbook | 7 | 10 |
| Patient brochure | 7 | 12 |
| Patient website (RI) | 0 | 11 |
| What to expect video (DI) | 13 | 0 |
| Myths facts video (DI) | 9 | 0 |
| HIV education video (DI) | 11 | 0 |
| ViiV Connect Assistance Video (DI) | 6 | 0 |
| Reminder service text (DI) | 7 | 0 |
| Appointment scheduler (DI) | 5 | 0 |
This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as ± 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Injections | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Dose 2 | 103 | 76 |
| Dose 3 | 77 | 57 |
| Dose 4 | 66 | 49 |
| Dose 5 | 50 | 45 |
| Dose 6 | 44 | 30 |
| Dose 7 | 35 | 27 |
| Dose 8 | 0 | 0 |
Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Number of PSPs Completing Target Number of Injections | 81 | 63 |
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs provided their insights into how APRETUDE has been incorporated into their daily lives, including factors that supported its delivery. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| APRETUDE Fitting life | 23 | 20 |
| Clinic staff supporting incorporation of APRETUDE into schedule | 15 | 10 |
| Booking appointments in advance | 13 | 11 |
| Easy to fit into life (convenience, etc.) | 16 | 8 |
| No transportation issues | 5 | 15 |
| Good fit with work schedule | 13 | 6 |
| Clinic hours aligned with patient schedule | 11 | 4 |
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs reported several challenges related to incorporating APRETUDE into their daily lives. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Discomfort | 14 | 11 |
| Clinic challenges | 4 | 6 |
| Work challenges | 2 | 5 |
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the facilitators for adherence to APRETUDE and the support provided to enable patient adherence. These facilitators were categorized as resources, support, patient communication and patient feasibility. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Resources: Communication (call, email and text) | 7 | 2 |
| Resources: Dedicated injection nurse for follow-up | 2 | 3 |
| Resources: Patient education about importance of adherence | 1 | 4 |
| Resources: Dedicated support staff for each step: education, authorization, etc | 4 | 0 |
| Resources: Flexibility of using oral PrEP for bridging when needed | 1 | 3 |
| Support: Scheduling appointments in advance | 4 | 3 |
| Support: Team dedicated for follow-up | 5 | 1 |
| Patient Communication: Increasing global communication | 6 | 5 |
| Patient Communication: Encouraging proactively engaging patients with scheduling | 6 | 3 |
| Patient Communication: Accessibility for patients for open line communication | 8 | 2 |
| Patient feasibility: APRETUDE is feasible for patients | 9 | 3 |
| Patient feasibility: Clinical staff making the process run smoothly | 4 | 4 |
| Patient feasibility: Working around patient schedule helps with feasibility | 3 | 3 |
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the barriers and challenges in enabling patient adherence to APRETUDE. The barriers were categorized as patient barriers and staff challenges. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Patient Barriers: Scheduling Barriers | 4 | 2 |
| Patient Barriers: Vulnerable Population | 2 | 2 |
| Patient Barriers: Traveling | 2 | 2 |
| Patient Barriers: Patients hard to contact (e.g., no phone access) | 2 | 2 |
| Staff Challenges: Concern about patients missing injection window | 4 | 2 |
| Staff Challenges: Not being able to contact patients who miss an appointment | 1 | 3 |
In this outcome measure, SSPs answered questions about their administration of the sexual health assessment (SHA). The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP |
|---|---|
| Yes | 14 |
| No And Not Planning to Use the Sexual Health Assessment | 14 |
| No But Planning to Use the Sexual Health Assessment | 4 |
| I don't know | 20 |
In this outcome measure, data shown below describes the number of PSPs to which the SHA was administered. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Yes | 39 | 35 |
| No | 15 | 13 |
| I don't know | 23 | 15 |
| Missing | 40 | 21 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Men Who Have Sex With Men (MSM) | Transgender Men (TGM) |
|---|---|---|
| Yes | 73 | 1 |
| No | 25 | 3 |
| I don't know | 36 | 2 |
| Missing | 55 | 6 |
In this outcome measure, data shown below describes the number of MSM and TGM who reported having had sex in the last 6 months. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Men Who Have Sex With Men (MSM) | Transgender Men (TGM) |
|---|---|---|
| No | 5 | 1 |
| Yes | 128 | 5 |
| I prefer not to answer | 1 | 0 |
| Missing | 55 | 6 |
In this outcome measure, data presented below shows the number of PSPs who expressed interest in PreP by responding to the question "Have you taken oral PreP in the last 6 months" and number of PSPs who had not heard of PreP.
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? — Yes | 70 | 61 |
| Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? — No | 30 | 15 |
| Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? — I don't know/prefer not to answer | 7 | 3 |
| Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? — Missing | 10 | 5 |
| Before enrolling in this study, had you heard of APRETUDE? — Yes | 68 | 58 |
| Before enrolling in this study, had you heard of APRETUDE? — No | 39 | 21 |
| Before enrolling in this study, had you heard of APRETUDE? — I don't know/prefer not to answer | 0 | 0 |
| Before enrolling in this study, had you heard of APRETUDE? — Missing | 10 | 5 |
| Have you taken oral PrEP in the last 6 months? — Yes | 77 | 65 |
| Have you taken oral PrEP in the last 6 months? — No | 26 | 11 |
| Have you taken oral PrEP in the last 6 months? — I don't know/prefer not to answer | 2 | 1 |
| Have you taken oral PrEP in the last 6 months? — Missing | 12 | 7 |
In this outcome measure, PSPs were asked if they had taken oral PreP in the last 6 months. PSPs who answered 'No' or 'I prefer not to answer' were further asked if they had ever taken oral PreP. Timeframe for evaluation of this outcome measure is through M12(equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Have you taken oral PrEP in the last 6 months? — Yes | 77 | 65 |
| Have you taken oral PrEP in the last 6 months? — No | 26 | 11 |
| Have you taken oral PrEP in the last 6 months? — I prefer not to answer | 2 | 1 |
| Have you taken oral PrEP in the last 6 months? — Missing | 12 | 7 |
| Have you ever taken oral PrEP — Yes | 5 | 1 |
| Have you ever taken oral PrEP — No | 11 | 0 |
| Have you ever taken oral PrEP — I prefer not to answer | 1 | 0 |
| Have you ever taken oral PrEP — Missing | 11 | 11 |
Perceptions of the sexual health assessment (SHA) among PSPs were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| SHA was received by PSPs | 16 | 0 |
| SHA was not received by PSPs | 3 | 0 |
| SHA received/not received- Missing | 4 | 0 |
| SHA found useful by PSPs | 15 | 0 |
| SHA not found useful by PSPs | 0 | 0 |
| SHA found useful/not useful- Missing | 1 | 0 |
In this outcome measure, SSPs provided insights regarding the use and implementation of SHA tool in their clinic/practice. The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP |
|---|---|
| The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Completely disagree | 1 |
| The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Disagree | 1 |
| The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Neither agree nor disagree | 3 |
| The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Agree | 8 |
| The Sexual Health Assessment is/will be easy to implement in my clinic/practice — Completely agree | 5 |
| The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Completely disagree | 1 |
| The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Disagree | 0 |
| The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Neither agree nor disagree | 3 |
| The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Agree | 10 |
| The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP — Completely agree | 4 |
| The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Completely disagree | 1 |
| The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Disagree | 0 |
| The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Neither agree nor disagree | 3 |
| The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Agree | 8 |
| The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients — Completely agree | 6 |
The Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize all modifications reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is from M2 to M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Number of Modifications | DI- SSP | RI- SSP |
|---|---|---|
| Trial Month 2 Modifications | 6 | 3 |
| Trial Month 3 Modifications | 4 | 8 |
| Trial Month 4 Modifications | 3 | 0 |
| Trial Month 5 Modifications | 3 | 5 |
| Trial Month 6 Modifications | 4 | 3 |
| Trial Month 7 Modifications | 1 | 4 |
| Trial Month 8 Modifications | 3 | 2 |
| Trial Month 9 Modifications | 2 | 0 |
| Trial Month 10 Modifications | 10 | 0 |
| Trial Month 11 Modifications | 2 | 0 |
| Trial Month 12 Modifications | 5 | 1 |
The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the types of modifications and adaptations reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Number of Modifications | DI - SSP | RI - SSP |
|---|---|---|
| Content: Modification made to the content of APRETUDE materials and tools | 12 | 4 |
| Evaluation: Modification made to the staff evaluate whether APPRETUDE is working | 5 | 3 |
| Training: Modification made to the staff delivering APRETUDE are trained | 22 | 0 |
| Contextual: Modification made to the overall implementation of APRETUDE injection delivered | 30 | 22 |
The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the perceptions and motivations of adaptations to implementation reported by SSPs using FRAME-IS. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Number of Modifications | DI - SSP | RI - SSP |
|---|---|---|
| Increase the number of patients with access to APRETUDE | 23 | 5 |
| Improve feasibility of the implementation effort | 19 | 8 |
| Improve fit with the clinical/practice setting | 18 | 10 |
| Increase satisfaction with the implementation effort | 17 | 11 |
| Speed up injection/implementation process | 17 | 12 |
PSP perceptions of adaptations to implementation strategies were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discussed their use of study resources and recommendations to staff for delivery of APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Discussed tools and resources | 21 | 20 |
| Positive feedback about tools and resources | 10 | 7 |
| Only used tools/resources in the beginning of PILLAR | 5 | 7 |
| Does not remember tools or resources | 3 | 5 |
| Resources were helpful | 2 | 4 |
| Negative feedback about tools and resources | 2 | 4 |
| Did not use (pay much attention to resources) | 2 | 2 |
| Recommendations to staff | 16 | 14 |
| Would not change anything | 4 | 3 |
| APRETUDE education within the community | 1 | 3 |
| Being culturally aware and non-judgmental | 2 | 2 |
| Support APRETUDE schedule | 2 | 1 |
| Discussion about post-Injection discomfort | 1 | 2 |
In this outcome measure, PSPs who completed the SHA and ISQ, describe the history of PrEP use and of sexual health assessment use for determination of PreP use during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Have you ever taken oral PrEP- Yes | 5 | 1 |
| Have you ever taken oral PrEP- No | 11 | 0 |
| Have you ever taken oral PrEP- Prefer not to answer | 1 | 0 |
| Have you ever taken oral PrEP- Missing | 11 | 11 |
| The SHA asked questions to determine if PrEP was right for me- Completely disagree | 2 | 1 |
| The SHA asked questions to determine if PrEP was right for me- Disagree | 0 | 1 |
| The SHA asked questions to determine if PrEP was right for me- Neither agree nor disagree | 5 | 7 |
| The SHA asked questions to determine if PrEP was right for me- Agree | 19 | 11 |
| The SHA asked questions to determine if PrEP was right for me- Completely Agree | 13 | 15 |
Reasons for choosing and switching to APRETUDE were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews among PSPs. In this outcome measure, PSPs shared previous oral PrEP experiences, comparisons of other forms of PrEP to APRETUDE, and reasons for preferring APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Oral PrEP used: Challenges remembering to take pill every day | 16 | 11 |
| Oral PrEP used: Side effects of oral PrEP | 6 | 3 |
| APRETUDE differences to oral PrEP: Better adherence and feeling more protected | 4 | 5 |
| APRETUDE differences to oral PrEP: APRETUDE More convenient than Oral | 6 | 2 |
| APRETUDE differences to oral PrEP: Less/ No side effects related to oral PrEP | 0 | 5 |
| Prefer APRETUDE over Oral PrEP: More convenient | 14 | 8 |
| Prefer APRETUDE over Oral PrEP: Less/No side effects | 1 | 5 |
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs answered ISQ regarding reasons for choosing to take APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| I want a prevention option that is more convenient for my life | 66 | 49 |
| I won't have to remember to take PrEP everyday | 63 | 45 |
| I do not have to worry or stress about missing a dose like oral PrEP | 55 | 47 |
| I want to try a new approach and see if it fits into my life | 43 | 27 |
| I will not have to worry about HIV every day | 43 | 27 |
General perceptions of facilitators for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss views of long-term use of APRETUDE, reasons to choose APRETUDE, and experiences with clinic staff. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Would consider APRETUDE as a long-term treatment | 19 | 17 |
| APRETUDE as long-term treatment provides protection | 12 | 6 |
| APRETUDE as long-term treatment provides peace of mind | 4 | 6 |
| APRETUDE as long-term treatment has concerns about insurance coverage long-term | 4 | 3 |
| APRETUDE as long-term treatment has convenience over oral PrEP | 5 | 1 |
| APRETUDE as long-term treatment taken as long as necessary | 0 | 5 |
| Reasons others may choose APRETUDE: Convenience and ease of use | 8 | 3 |
| Reasons others may choose APRETUDE: Health and prevention | 4 | 5 |
| Global judgement of recommend to others | 13 | 14 |
| Experiences of care: Discussed interactions with clinic staff | 21 | 21 |
| Experiences of care: Clinic staff were friendly and kind | 17 | 19 |
| Experiences of care: PSP was treated with respect | 15 | 15 |
| Experiences of care: Clinic staff were knowledgeable | 12 | 7 |
| Experiences of care: Shared decision making | 10 | 9 |
| HIV/STI testing: Testing frequency was acceptable | 13 | 15 |
| HIV/STI testing: Positive experience with scheduling HIV/ STI testing | 11 | 11 |
| Reported whether they discussed APRETUDE with family / friends | 21 | 18 |
| Has discussed APRETUDE with partner(s) | 11 | 9 |
| Peers have started PrEP | 10 | 7 |
| Uptake of PrEP by Friends | 3 | 2 |
General perceptions of barriers for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss challenging views of or experiences with APRETUDE receipt. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
| Participants | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Would not consider APRETUDE as a long-term treatment | 1 | 3 |
| Cost Challenges | 6 | 3 |
| Challenges with switching insurance carriers | 0 | 4 |
General perceptions of facilitators for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss clinic culture and implementation motivations. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Supportive leadership for implementation | 11 | 11 |
| Leadership willing to help/support | 6 | 8 |
| Leadership being actively involved in the process | 4 | 5 |
| APRETUDE positively accepted | 10 | 5 |
| Team adaptability | 8 | 3 |
| Staff being supportive of the clinic offering APRETUDE | 11 | 6 |
| Aiming to improve patient's health | 2 | 2 |
General perceptions of barriers for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss feelings and perspectives while implementing APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
| Participants | DI - SSP | RI - SSP |
|---|---|---|
| Staff having mixed feelings | 9 | 4 |
| Initial negative response due to extra workload | 2 | 2 |
Collected over Serious adverse events (SAEs) were reported from signing of informed consent (a period starting up to 90 days before the first dose in Month 1) to Month 12 (study completion). Non serious Drug related AEs were reported from Month 1 (first dose) to Month 12 (study completion).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dynamic Implementation (DI) - PSP | 0/117 (0%) | 1/117 (0.9%) | 5/117 (4.3%) |
| Routine Implementation (RI) - PSP | 0/84 (0%) | 0/84 (0%) | 6/84 (7.1%) |
| Event | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Clavicle fractureInjury, poisoning and procedural complications | 1/117 | 0/84 |
| Rib fractureInjury, poisoning and procedural complications | 1/117 | 0/84 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/117 | 0/84 |
| Event | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP |
|---|---|---|
| Injection site painGeneral disorders | 2/117 | 4/84 |
| FatigueGeneral disorders | 2/117 | 2/84 |
| Injection site reactionGeneral disorders | 0/117 | 1/84 |
| Peripheral swellingGeneral disorders | 0/117 | 1/84 |
| DiarrhoeaGastrointestinal disorders | 0/117 | 1/84 |
| Depressed moodPsychiatric disorders | 1/117 | 1/84 |
| Libido decreasedPsychiatric disorders | 0/117 | 1/84 |
| Back painMusculoskeletal and connective tissue disorders | 0/117 | 1/84 |
| PainGeneral disorders | 1/117 | 0/84 |
| NauseaGastrointestinal disorders | 1/117 | 0/84 |
Baseline characteristics for SSPs were not collected as it was not required as per study design.
| Age, Continuous(Years) | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP | Total |
|---|---|---|---|
| Mean | 37.6 ± 11.16 | 37.8 ± 10.76 | 37.7 ± 10.97 |
| Sex/Gender, Customized(Participants) | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP | Total |
|---|---|---|---|
| Cisgender Man | 107 | 82 | 189 |
| Transgender Man | 10 | 2 | 12 |
| Race/Ethnicity, Customized(Participants) | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 6 | 2 | 8 |
| Black of African American | 19 | 29 | 48 |
| Multiple Races | 2 | 4 | 6 |
| Other, not specified | 2 | 0 | 2 |
| Unknown | 15 | 2 | 17 |
| White | 72 | 47 | 119 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from May 2022 to primary completion in Aug 2024, 26 months.
Results were first posted in Dec 2025, 1 year 4 months after primary completion.
Of 91 phase 4 interventional studies under HIV Infections, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir